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Abstract:
Delivery of MicroRNA with CXCR4-Targeted Nanoparticles in Metastatic Cancer
Treatment
Ying Xie, Ph.D.
University of Nebraska Medical Center, 2018
Supervisor: David Oupický, Ph.D.
Metastasis is the main contributor to cancer-associated deaths. Inhibition of
CXCR4 emerged as one promising approach in metastatic cancer therapy. MiRNAs
represent a new class of therapeutics for cancer treatment through RNA interferencemediated gene silencing. Polymeric CXCR4 antagonist (PCX) is a dual-functional
polycation to inhibit CXCR4 and deliver nucleic acids. This dissertation hypothesized
that blockade of CXCR4 by PCX combined with delivery of miRNA cooperatively
enhances metastatic cancer therapy.
In chapter 1, an overview of CXCR4 inhibition, miRNA delivery and CXCR4
targeted nanomedicine in cancer therapy is given.
Chapter 2 reports that PCX can effectively deliver miR-200c mimic and that the
combination treatment consisting of PCX and miR-200c results in cooperative
antimigration activity by coupling the CXCR4 blockade with epithelial-to-mesenchymal
transition inhibition in the cholangiocarcinoma (CCA) cells. The ability of the combined
PCX/miR-200c treatment to obstruct two migratory pathways represents a promising
antimetastatic strategy in CCA.
Chapter 3 describes that blockade of CXCR4 by PCX combined with the
inhibition of hypoxia-inducible miR-210 can cooperatively enhance therapeutic efficacy in

CCA. PCX had a broad inhibitory effect on cell migration, effectively delivered anti-miR210, and downregulated miR-210 expression in CCA cells. PCX/anti-miR-210
nanoparticles showed cytotoxic activity towards CCA cells and reduced cancer stem-like
cells. The nanoparticles reversed hypoxia-induced drug resistance and sensitized CCA
cells to gemcitabine and cisplatin combination treatment. Systemic treatment with the
nanoparticles in CCA xenograft model resulted in prominent combined antitumor activity.
In chapter 4, PCX effectively delivered both siKRAS and miR-210 inhibitor into
pancreatic cancer (PC) cells and induced combined cell killing effect. IP injection of
nanoparticles targeted to orthotopic PC tumor. The IP injected combination
nanoparticles achieved improved survival in KPC-derived mice through inhibition both
primary tumor growth and metastasis. The nanoparticles represent a promising dualfunction delivery platform for siRNA/miRNA codelivery and provide safe and effective
nanomedicines for metastatic PC therapy.
Results of this thesis and future directions are given in Chapter 5.
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Chapter 1 – Introduction
Please note that part of the content of this chapter was published in Wiley
Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology (Xie, Wang et al, 2018)
[1]. As the first author, I wrote the paper. Prof. Oupický, Dr. Jing Li, Dr. Yazhe Wang and
Yu Hang gave suggestions to write the manuscript. All the authors agreed with including
their work in this dissertation.
Cancer is a major public health problem and a leading cause of mortality
worldwide. Metastasis is the main contributor to cancer-associated deaths [2]. The
heterogeneity of cancer, combined with multiple gene mutations during tumorigenesis
and tumor progression, makes curing cancer a daunting challenge. Recently,
combination of chemotherapeutics with RNA interference (RNAi), mainly small
interfering RNA (siRNA) and microRNA (miRNA), emerged as an effective strategy in
cancer treatment. These combination therapies demonstrate potentially great benefits in
targeting multiple cancer-associated pathways, inhibiting metastasis and overcoming
adaptive drug resistance [3, 4]. However, this combination treatment is limited by a lack
of efficacious delivery systems for simultaneous delivery of small-molecule drugs and
siRNA/miRNA. Due to the physicochemical differences between the two types of agents,
it is a significant challenge to develop delivery systems for combinations of small
molecule drugs and siRNA/miRNA. Among the available delivery systems, polymeric
nanoparticles have been the most successful delivery approaches in drug/nucleic acid
combinations [4, 5]. Typical polymeric nanoparticles are composed of pharmacologically
inert polymer suitable for encapsulation of both types of therapeutic agents. Recently,
alternative approaches have focused on the development of pharmacologically active
nanoparticles and polymers to achieve delivery of drug/nucleic acid combinations [6-9].

2

The chemokine receptor CXCR4 is an important emerging target for developing
combination delivery strategies for improved cancer therapy [10, 11]. CXCR4 is an
especially promising target in antimetastatic therapies because of its crucial role in
metastatic spread of multiple types of human cancer [12, 13]. Mounting evidence also
supports the potential of improving chemotherapy and immunotherapy through its
combination with CXCR4 antagonists [14-17]. As a result, various CXCR4-targeted drug
delivery systems, including liposomes, nanoparticles, dendrimers, lipoplexes, and
polyplexes have been developed for improved cancer therapy [10]. Recently, our group
have reported the synthesis of a series of polycations with the ability to simultaneously
inhibit CXCR4 and deliver nucleic acids to cancer cells. We have successfully employed
these polymeric CXCR4 inhibitors (PCX) to deliver functional siRNA and miRNA for
combination cancer therapy [18-21]. More recently, we have successfully prepared
chloroquine-containing polycations as efficient miRNA delivery vectors with improved
endosomal escape and antimigratory activity through CXCR4 inhibition in cancer cells
[22]. Next, we will introduce these dual functional CXCR4 targeted polycations and
discuss the combination strategies based on CXCR4 targeted nanomedicines for cancer
therapy.
1.1 CXCR4 as a therapeutic target in cancer
CXCR4 and its chemokine ligand (CXCL12) are two key factors in the tumor
growth, metastasis, angiogenesis, and cancer cell-microenvironment interaction, which
make them promising targets for cancer therapy.
1.1.1 CXCR4/CXCL12 axis
Chemokine receptors are a large family of proteins that mediate chemotaxis of
cells towards a gradient of chemokines. Based on the location of conserved cysteine
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residues, chemokine receptors are classified into four groups (C, CC, CXC and CX3C).
There are over twenty different chemokine receptors which all belong to the G-protein
coupled receptor family. In tumors, the system of chemokines and chemokine receptors
modulates the trafficking of cells into and out of the tumor microenvironment and
especially mediates crucial steps of the metastasis of tumor cells. Although different
types of cancer have varied expression profiles of chemokine receptors, CXCR4 is the
most widely expressed chemokine receptor in human cancers. CXCR4 is a G-protein
coupled receptor with a seven-transmembrane structure. CXCR4 exerts its biological
effect by binding with its specific ligand CXCL12 (also known as stromal derived factor-1,
SDF-1). Through activating multiple downstream signaling pathways (mainly including
PI3K, MAPK, and Erk1/2), CXCR4/CXCL12 axis regulates a number of different cellular
processes, which includes alteration of gene expression, actin polymerization, cell
skeleton rearrangement, cell survival, migration and invasion [23, 24].
1.1.2 CXCR4 in cancer and metastasis
CXCR4 expression has been found in more than 20 major human cancer types,
including breast, ovarian, prostate, pancreatic, melanoma, and renal cell carcinoma [23].
The upregulation of CXCR4 is highly dependent on multiple transcription factors, growth
factors, and hypoxia-inducible factors [25, 26]. A significant correlation between CXCR4
expression and cancer metastasis has been demonstrated by many preclinical and
clinical studies. For example, a clinical study concluded that elevated expression of
CXCR4 in primary breast tumors is associated with a higher likelihood of developing
bone metastases [27]. Another study showed significant correlation between CXCR4
expression and lymph node metastasis [28]. High CXCR4 expression also indicates poor
survival and enhanced aggressiveness of cancers and can be used as an independent
prognostic marker [29]. CXCR4 can activate focal adhesion complexes and matrix
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metalloproteinases, which mediates degradation of extracellular matrix and facilitates the
invasion of cancer cells. Then, the CXCL12 concentration gradients drive the movement
of CXCR4-expressing cancer cells in the circulation and contribute to the process of
extravasation and organ-specific metastasis. For instance, bone marrow, lungs, brain,
liver and lymph nodes exhibit elevated expression levels of CXCL12 and represent the
most common organs for homing of cancer metastasis in cells that express the CXCR4
receptor [30].
1.1.3 CXCR4 as target for cancer therapy
Various strategies have been developed to inhibit CXCR4/CXCL12 axis for
anticancer applications. Among them, specific CXCR4 antagonists showed the best
effects. A small molecule CXCR4 antagonist Plerixafor (AMD3100) has already been
approved by the FDA for clinical use in stem cell mobilization [31]. Besides small
molecules, CXCR4-binding peptides and siRNA silencing of CXCR4 gene have also
been reported to be capable of inhibiting CXCR4-mediated processes in anticancer
therapy [32-36]. The inhibition of CXCR4 with these therapeutic agents is highly
efficacious for cancer therapy through inhibiting metastasis, sensitizing tumors to
chemotherapy and radiotherapy, and boosting immunotherapy [37-39]. In the past
decade, development of multiple nanomedicines that target CXCR4 have been also
reported (Figure 1.1). First, CXCR4 can serve as a target for ligand-mediated
enhancement of delivery and molecular imaging. CXCR4-binding small molecule organic
ligands, CXCR4-binding peptides or anti-CXCR4 antibodies can be attached to the
surface of nanoparticles for active targeting to cancer cells for improved therapy and
imaging [40, 41]. For example, gold nanoclusters functionalized with AMD3100 were
used for targeted positron emission tomography (PET) imaging of CXCR4 in primary
tumors and metastases in an orthotopic breast cancer model [42]. Moreover, inhibition of
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CXCR4 through CXCR4 siRNA or CXCR4 ligands can be considered as effective
approach for cancer therapeutic nanomedicines [36, 43-46]. For example, CXCR4targeted lipid-coated poly(lactic-co-glycolic acid) (PLGA) nanoparticles modified with
AMD3100 systemically delivered sorafenib into liver cancer, resulting in effective
sensitization of tumors to sorafenib treatment and lung metastasis inhibition [44].
1.2 Small RNA delivery
RNA interference (RNAi) is a natural biological mechanism in which RNA
molecules inhibit gene expression or translation by neutralizing target mRNA molecules.
RNAi based agents, mainly including siRNA and miRNA, are able to knock down the
oncogenes by targeting related mRNA expression, which make them powerful
approaches for cancer therapy [47, 48].
1.2.1 SiRNA
siRNAs are synthetic RNA duplexes (19 to 25 bp in length) with 3' dinucleotide
overhangs designed to specifically target a particular mRNA for degradation. SiRNAmediated RNAi pathway starts with the processing of dsRNA by DICER to siRNA which
is then loaded into the RNA inducing silencing complex (RISC) (Figure 1.2). The
passenger strand of siRNA is cleaved by AGO2 which is a component of RISC. Then,
the guide strand of siRNA guides the activated RISC to the target mRNA. Finally, the
complete complementary binding between the guide strand and mRNA leads to the
cleavage of mRNA of target gene [4, 48, 49]. Through silencing of key oncogenes,
siRNA is capable of modulating or selectively blocking biological processes that are the
defining hallmarks of cancer, which make it potentially an effective therapeutic approach
for cancer [50].
1.2.2 MiRNA
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MiRNAs are small (∼22 nucleotide) noncoding endogenous RNAs that posttranscriptionally regulate gene expression. In the nucleus, the transcription of miRNA
gene is carried out by RNA polymerase II to produce pri-miRNA, which is then cleaved
by Drosha to form pre-miRNA (Figure 1.2). Pre-miRNA is transported by Exportin 5 to
the cytoplasm. In the cytoplasm, pre-miRNA is processed by Dicer into mature miRNA.
Then, miRNA is loaded into RISC. The passenger strand is discarded. The remaining
guide strand guides the miRISC to the target mRNA through partially complementary
binding. Finally, the target mRNA is inhibited via translational repression, degradation or
cleavage [48, 51]. Due to the imperfect pairing, a single microRNA is capable of
simultaneously targeting different genes, showing the characteristic of multiple targeting.
MiRNAs regulate a wide range of cellular pathways and modulate the expression of
nearly 30% of all human proteins. Dysregulation of miRNA often results in pathological
states such as cancer. MicroRNAs function as tumor suppressors or oncogenes and
play an important role in tumorigenesis, tumor growth, angiogenesis, and metastasis
[52]. Hence, inhibition of overexpressed oncogenic microRNAs or restitution of
downregulated tumor-suppressor microRNAs provides a highly promising approach to
treat cancer [53].
1.2.3 Small RNA delivery
Both siRNA and miRNA are highly effective therapeutic agents for cancer.
However, their clinical use is limited by multiple hurdles, such as stability, off-target
effect and poor efficiency of delivery. Although proper chemical modification can improve
the stability and reduce off-target effect, poor delivery is still a main challenge in
translating therapeutic siRNAs/miRNAs into clinic [54, 55]. Since they have similar
physicochemical properties (double-stranded RNAs with about 22 nucleotides) and the
same intracellular site of action (cytoplasm), similar delivery systems can be utilized for
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both siRNA and miRNA. An ideal delivery system is expected to sequentially overcome
multiple biological barriers, mainly including nucleases degradation, reticuloendothelial
system (RES) clearance, poor tumor tissue penetration and intracellular uptake,
lysosomal entrapment, and intracellular RNA release [56, 57].
Viral vectors and non-viral vectors represent the two main types of delivery
technologies for siRNA/miRNA. Non-viral vectors show advantages over viral vectors in
terms of safety and represent a potential option for clinical application. Widely used nonviral approaches include polymer-based and lipid-based delivery systems. Cationic
polymers (polycations) and cationic lipids bind with anionic siRNA/miRNA through
electrostatic interactions which leads to the formation of nanosized polyplexes or
lipoplexes, which protect them from degradation and facilitate transport across cellular
membranes [48]. To meet the requirement of combination RNAi therapy and traditional
small molecule therapy, many delivery systems have been reported to co-deliver small
molecule agents and RNAi therapeutics in the past decade. Among the available
delivery systems, polymeric nanoparticles have been the most successful delivery
approaches in drug/RNAi therapeutic combinations. Typical polymeric nanoparticles are
composed of pharmacologically inert polymer suitable for encapsulation of both types of
therapeutic agents [3]. However, the manufacturing complexity and unsatisfactory drug
loading ability of the traditional nanoparticles remain a significant hurdle for their clinical
translation. Recently, alternative approaches from our lab have developed
pharmacologically active nanoparticles based on polymeric drugs to achieve delivery of
drug/nucleic acid combinations [6]. The uniquely designed polymeric drug nanoparticles
have several advantages, including simpler formulation and high content of active
agents that make them suitable candidates for delivery of drug/RNA combinations. In
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particular, a series of CXCR4 targeted polymeric drug nanoparticles represent a new
generation of drug/RNAi delivery vectors for combination anticancer therapy.
Both CXCR4 inhibition and siRNA/miRNA delivery are important approaches for
cancer therapy. CXCR4 targeted nanomedicines delivering functional siRNA/miRNA
represent an effective choice for combinational cancer therapy. These newly developed
nanomedicines include polyplexes, lipid nanoparticles, peptide carriers, lipopolymer
complexes and fusion proteins (Table 1). Among the CXCR4 targeted nanomedicines,
we will focus on polymeric CXCR4 antagonists and polymeric chloroquines.
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Figure 1.1. Main approaches utilizing CXCR4 in cancer nanomedicine.

10

Figure 1.2. Gene silencing mechanisms of siRNA and miRNA. (Reprinted with
permission from Ref [48])
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Table 1. Example of CXCR4-targeted nanomedicines delivering siRNA/miRNA in cancer therapy.
CXCR4
Delivery system
Delivered
Application
References
targeting
cargo
moiety
AMD3100
Polyplexes
PLK1 siRNA Simultaneously inhibit migration
[58]
(PCX-1)
through CXCR4 antagonism and
kill cells through siPLK1 (in vitro)
AMD3100
Polyplexes
NCOA3
Increase tumor perfusion by
[21]
(PCX-1)
siRNA
siNCOA3, simultaneously inhibit
tumor growth and metastasis (in
vivo)
Monocyclam Polyplexes
MiR-200c
Combined inhibition of cancer
[59]
(PCX-2)
mimic
cell invasiveness by CXCR4
antagonism and EMT inhibition
(in vitro)
AMD3465
Polyplexes (PMiR-200c
Combined inhibition of cancer
[60]
SS-AMD)
mimic
cell migration by CXCR4
antagonism and EMT inhibition
(in vitro)
Chloroquine
Polyplexes
MiR-210
Facilitate endosome escape,
[22]
(PCQ)
inhibitor
simultaneously inhibit migration
and kill cells (in vitro)
AMD3100
Lipid
VEGF
Overcome tumor evasion of
[61]
nanoparticles
siRNA
antiangiogenic therapy, inhibit
tumor growth and metastasis (in
vivo)
Peptide
Modular peptide- VEGF
Targeted siRNA delivery into
[62]
based carrier
siRNA
CXCR4-expressing cancer and
endothelial cells for inhibition of
migration (in vitro)
CXCR4
Lipopolymer
CXCR4
Decrease CXCR4 expression for
[63]
siRNA
complexes
siRNA
acute myeloid leukemia therapy
(in vitro)
CXCR4
Fusion protein
CXCR4
CXCR4 knockdown by siRNA
[36]
siRNA
siRNA
effectively inhibited breast tumor
growth and metastasis (in vivo)
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1.3 Cyclam-based polymeric CXCR4 antagonists (PCX)
1.3.1 Polymer design and development
Blockade of CXCR4 with specific antagonists can inhibit metastasis and control
the growth of the primary tumors [64]. Cyclam derivatives such as AMD3100 are the
most widely investigated CXCR4 antagonists which act through inhibiting CXCL12
binding and subsequent CXCR4 signaling [65-67]. AMD3100 contains six secondary and
two tertiary amines (Figure 1.3A). Not all of the eight amines are required for binding to
the CXCR4 receptor and its pharmacologic function. The redundant amine groups can
be used for chemical modification while still maintaining CXCR4 inhibition activity [68].
The presence of the protonizable amines provides AMD3100 with positive charge, which
makes it a suitable building unit for synthesis of polycations for nucleic acid delivery.
Based on this rationale, our group have synthesized the first generation of polymeric
CXCR4 antagonists (PCX-1) (Figure 1.3A), polymeric AMD3100, by direct Michael-like
addition polymerization of AMD3100. The synthesized PCX-1 not only retained the
CXCR4 inhibitory activity of parent AMD3100 but also successfully delivered nucleic
acids to cancer cells [18, 20].
Although PCX-1 was well suited for the proof-of-principle studies, the ability to
control the polymerization reaction was severely compromised by the presence of six
reactive secondary amines in the chemical structure of AMD3100, which resulted in the
generation of highly branched polymers. The random chemical substitution of AMD3100
in PCX-1 also decreased the relative CXCR4 inhibitory activity when compared with the
parent AMD3100. To overcome the disadvantage of PCX-1, we then developed the
second generation of the poly(amido amine) CXCR4 antagonists (PCX-2) with improved
presentation of the CXCR4-binding moieties and better controlled polymerization. Unlike
PCX-1 which was based on AMD3100, the linear PCX-2 was prepared by the
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polymerization of newly synthesized CXCR4-inhibiting monocyclam monomers (Figure
1.3A). PCX-2 showed improved ability to inhibit CXCR4 when compared with the
monomers. PCX-2 inhibited cancer cell invasion in vitro and presented CXCR4
antagonism in vivo to mobilize leukocytes from bone marrow to peripheral blood.
Moreover, the dual function PCX-2 was also capable of delivering DNA into cancer cells
[19].
Chemical modification of the PCX polymers was performed to further improve the
activity of PCX to systemically deliver functional nucleic acids for cancer therapy. To
improve in vivo applicability, polyplexes are often modified with poly(ethylene glycol)
(PEG) to shield the surface charges and improve colloidal stability by steric stabilization
[69, 70]. Accordingly, PEG modification of PCX was investigated by grafting PEG chains
to form PEG-PCX. We found that optimized PEG-PCX retained the desirable CXCR4
antagonism and capability of PCX to inhibit cancer cell invasion, while at the same time
allowing to improve safety and colloidal stability of the PCX polyplexes [71].
Furthermore, we were able to further balanced the polymer hydrophobicity by grafting
PCX with cholesterol and prepared amphiphilic Chol-PCX. When compared with simple
PCX polyplexes, the optimized Chol-PCX polyplexes increased colloidal stability and
greatly improved siRNA transfection in the presence of serum, all the while retaining
strong CXCR4 inhibitory activity [58]. Overall, PEG-PCX and Chol-PCX were
successfully developed as potential vectors for systemic in vivo delivery of nucleic acids.
1.3.2 PCX-mediated delivery of siRNA and miRNA to cancer cells
After successful development of the CXCR4 inhibiting polymers PCX, we tested
their ability to deliver suitable siRNA or miRNA for combined cancer therapy. In the first
example, we focused on PCX/siRNA polyplexes for pancreatic cancer (PC) therapy. PC
is one of the most aggressive malignancies with intense desmoplasia, widespread
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metastasis and inherent chemoresistance. Nuclear receptor co-activator-3 (NCOA3) is a
critical modulator of the expression of mucins in PC. Silencing of NCOA3 with siRNA in
PC cells downregulates the expression of mainly two mucins, MUC1 and MUC4, which
are critical for PC progression [72]. Besides mucins, NCOA3 upregulates the expression
of multiple chemokines that are responsible for the recruitment of immune cells to
pancreatic tumors, perpetuation of pro-inflammatory conditions, and activation of
pancreatic stellate cells. As a result, NCOA3 is a suitable target for siRNA nanomedicine
design which aims to modulate PC tumor microenvironment by decreasing desmoplasia,
increasing perfusion and enhancing drug delivery to tumor. In addition to the tumor
microenvironment modulation by NCOA3 silencing, blockade of CXCR4 is another
effective approach to inhibit PC metastasis and progression. We thus combined the two
strategies together, using optimized formulation of PCX/siNCOA3 polyplexes to
simultaneously target CXCR4 and NCOA3 in PC (Figure 1.4). Chol-PCX showed
maximum CXCR4 antagonism, NCOA3 silencing and inhibition of PC cell migration in
vitro. Furthermore, PCX/siNCOA3 polyplexes showed great potential in sensitizing PC
cells to chemotherapy. More importantly, the polyplexes showed improved antitumor
therapy in an orthotopic mouse model of metastatic PC after systemic delivery. The
polyplexes significantly inhibited primary tumor growth, which was because of a
decrease in tumor necrosis and increased tumor perfusion. The polyplexes also showed
significant antimetastatic effect as demonstrated by effective suppression of metastasis
to distant organs. Overall, PCX/siNCOA3 polyplexes represent a highly promising
combination approach for modulating tumor microenvironment in metastatic PC [21].
In addition to siRNA delivery, PCX also provide effective delivery activity for
therapeutic miRNA as demonstrated in a study focused on delivery of metastasisregulating miRNA for cooperatively enhanced anti-invasive effect in multiple types of
cancer cells. The invasion and metastasis of cancer cells are regulated by multiple
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factors, which includes not only CXCR4 but also multiple miRNAs. For example,
increasing intracellular levels of miR-200c decreased the extent of the epithelial-tomesenchymal transition (EMT) and inhibited cell migration and invasion in cancer cells
[73]. Combining the CXCR4 antagonism with the action of miR-200c mimic was thus
expected to cooperatively enhance the inhibition of the migration of cancer cells. Based
on this rationale, we prepared PCX-2 polyplexes carrying miR-200c mimic (Figure 5).
PCX-2 polyplexes effectively delivered miR-200c mimic into cancer cells. By coupling
the CXCR4 blockade with miR-200c-induced EMT inhibition, the polyplexes achieved
cooperative antimigration activity (Figure 1.5A and B) [59]. Moreover, an N-(2hydroxypropyl)methacrylamide (HPMA)-based self-immolative polymeric prodrug of a
CXCR4 antagonist, AMD3465 (P-SS-AMD) (Figure 1.5C), also effectively delivered
miR-200c and led to the combinational inhibition of cancer cell migration [60]. Overall,
PCX/miR-200c treatment is an effective antimetastatic strategy that combines inhibition
of two important cell motility pathways.
1.3.3 Mechanism of action of PCX polyplexes
Even though we have experimentally confirmed the dual function of PCX/RNA
polyplexes to inhibit CXCR4 and deliver small RNA [58], the specific mechanism of
action remained unclear because of the seemingly conflicting demands on the system
(siRNA delivery vs. CXCR4 inhibition). We have formulated three hypotheses depicted in
Figure 1.6 to explain the mechanism of action. First, as all polyplexes, PCX/RNA are
prepared with excess PCX and it is the excess polymer that is responsible for the
immediate CXCR4 antagonism. This has been shown by increased CXCR4-dependent
anti-migration activity with increasing PCX/siRNA w/w ratio [58]. Second, PCX bound to
siRNA is released after intracellular siRNA delivery and polyplex disassembly. This
mode of action results in delayed CXCR4 inhibition effect, either via binding intracellular
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CXCR4 during recycling or via PCX excretion from the cells and binding the plasma
membrane CXCR4 on cancer cells. Third, in case of intracellularly degradable PCX, the
small molecule degradation products containing the CXCR4-binding cyclam moieties
may further contribute to the CXCR4 inhibition. Improved understanding of the
mechanism of action will contribute to further improvement of the antitumor and
antimetastatic activity of the PCX polyplexes.
Another concern in developing PCX has been related to optimizing properties of
the formulations with two active agents (CXCR4 inhibitor and siRNA/miRNA). Single
formulation of two active agents is often technically challenging, and in many cases, it
may be easier to use two single-agent formulations. However, several unique properties
of PCX greatly simplify the process of optimizing pharmacologic activity of the dual
PCX/siRNA polyplexes and justify their development. The most important one is a broad
therapeutic window of PCX, which gives us great leeway in optimizing the formulation for
effective siRNA/miRNA delivery without significant concerns about the CXCR4 activity.
For example, the effective dose (EC50) of the most active PCX is only 0.021 μg/mL, while
its toxic dose (LD50) is more than 8,000-times higher (171 μg/mL) [19]. In a typical siRNA
(10 nM) silencing experiment with polyplexes formulated at PCX/siRNA w/w ratio of 5,
the PCX concentration would be 0.665 μg/mL (i.e., 30-times above EC50). Thus, at the
anticipated siRNA concentration range, changes in PCX concentrations will have
minimal effect on its CXCR4 activity.
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Figure 1.3. Chemical structure of (A) AMD3100 and cyclam-based polymeric CXCR4
antagonists (PCX) and (B) hydroxychloroquine and chloroquine-based CXCR4
antagonists (PCQ) (Red color indicates the CXCR4-binding repeating unit in the
polymers).
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Figure 1.4. Mechanism of action of PCX/siNCOA3 polyplexes in pancreatic cancer
therapy. (Reprinted with permission from Ref [21])
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Figure 1.5. (A) Proposed mechanism of action of PCX/miR-200c polyplexes. (B)
Combined inhibition of cancer cell migration. (Reprinted with permission from Ref [59])
(C) Chemical structure of an HPMA-based self-immolative polymeric prodrug of a
CXCR4 antagonist, AMD3465 (P-SS-AMD). (Reprinted with permission from Ref [60])
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Figure 1.6. Proposed mechanisms of PCX/RNA polyplexes. (1) Excess PCX of the
polyplexes formulation is responsible for the immediate CXCR4 antagonism. (2) The
disassembly of polyplex releases both small RNA and PCX. Functional small RNA
silences oncogene through RNAi mechanism. These released PCX results in delayed
CXCR4 inhibition effect via binding intracellular CXCR4 during recycling or via PCX
excretion from the cells and binding the plasma membrane CXCR4 on cancer cells. (3)
In case of intracellularly bioreducible PCX (rPCX), the small molecule degradation
products containing the CXCR4-binding cyclam moieties further contribute to the CXCR4
inhibition.
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1.4 Chloroquine-based CXCR4 antagonists (PCQ)
1.4.1 Polymer development
Chloroquine (CQ) is a widely used antimalarial drug. In recent years, the
potential benefits of CQ in anticancer therapies have been also reported mainly due to
its effects on autophagy and cholesterol metabolism.[74-77] Recently, the ability of CQ
to inhibit CXCR4/CXCL12 axis has also been reported and successfully used in the
treatment of solid tumors [78]. CQ was able to inhibit CXCL12-mediated invasion and
proliferation of PC cells and improve survival of tumor-bearing mice when combined with
gemcitabine treatment [79]. Despite its promise, CQ is a poor (mM) inhibitor of CXCR4
when compared with existing specific nM inhibitors like AMD3100. Thus, we aimed to
improve the CXCR4-inhibiting activity of CQ by taking advantage of the multivalency
effect by conjugating multiple CQ molecules to a polymeric carrier. We have synthesized
CQ-containing copolymers (PCQ) by copolymerization of methacryloylated hydroxy-CQ
(HCQ) and HPMA. PCQ-1 enhanced inhibition of cancer cell migration and invasion in
vitro, and improved antimetastatic activity in vivo with lower toxicity when compared with
the parent HCQ. The effective inhibition of the CXCR4/CXCL12 axis has been confirmed
as one mechanism of the PCQ antimetastatic activity [80, 81]. Besides HPMA-based
PCQ, our group reported another PCQ drug, chloroquine-modified hydroxyethyl starch
(CQ-HES) which was synthesized by conjugation of HES with HCQ by a
carbonyldiimidazole coupling. CQ-HES was able to target CXCR4 signaling and improve
inhibition of migration and invasion of PC cells when compared with HCQ [82]. Overall,
PCQ represents a new generation of safe and effective CXCR4 inhibitors for metastatic
cancer therapy.
Besides CXCR4 antagonism, CQ is also a widely used chemical endosomolytic
agent to improve in vitro transfection of polyplexes. Simple cotransfection of polyplexes
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with free CQ enhances the cytoplasmic delivery of nucleic acids [83]. However, CQ
cotransfection is difficult to be used in vivo because in order to achieve the functional
levels, toxic doses of CQ are required. To overcome the limitations of CQ as endosomal
agent in vivo, covalent conjugation of CQ to the nanoparticles improved siRNA delivery
in vivo by enhancing endosomal escape [84]. Thus, conjugation of CQ to polycations
was also expected to improve endosomal escape of polyplexes. Hence, we aimed to
prepare CQ-conjugated polycation for both CXCR4 antagonism and improved
endosomal escape. Recently, we reported the synthesis of CQ-containing 2(dimethylamino)ethyl methacrylate (DMAEMA) copolymers (PCQ-2) by reversible
addition–fragmentation chain-transfer polymerization. After careful optimization of both
polymer molecular weight and CQ content in the polymer, the best performing PCQ-2
polyplexes presented the expected dual function through not only inhibiting the migration
of cancer cells but also facilitating the endosomal escape for cytoplasm delivery of
miRNA (Figure 1.7) [22].
1.4.2 RNA delivery by PCQ
After successful preparation of PCQ-2, we then aimed to deliver suitable siRNA
or miRNA for cancer therapy. Intratumoral hypoxia is a hallmark of cancer due to a
structurally and functionally disturbed microcirculation, with deterioration of the diffusion
geometry, and of tumor-associated anemia [85]. As a key factor in tumor progression,
hypoxia induces cancer metastasis and increases the resistance of cancer cells to
chemotherapy, radiotherapy and photodynamic therapy [86-88]. Hypoxia is also able to
induce and stabilize CXCR4 expression in cancer [89, 90]. MiR-210 is a major hypoxiainducible miRNA which is overexpressed in multiple types of cancers [91, 92]. MiR-210
controls a wide range of biological processes, including cell proliferation, apoptosis,
differentiation, DNA repair, cell metabolism, metastasis, and antitumor immune
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responses [93, 94]. Hence, miR-210 inhibition with anti-miR-210 provides a valid target
for the treatment of cancer. Accordingly, we prepared PCQ polyplexes to deliver antimiR-210. Besides retaining the antimigration activity by CXCR4 antagonism, PCQ
polyplexes improved the delivery of anti-miR-210 to cancer cells by facilitating
endosomal escape. Moreover, through inhibition of miR-210 function, PCQ/anti-miR-210
polyplexes improved anticancer activity by inducing significant cell killing in cancer cells.
These results further validate the use of PCQ as a efficacious polymeric drug platform in
combination anti-metastatic and anticancer miRNA therapeutic strategies [22].
1.5 CXCR4-targeted nanoparticles
1.5.1 CXCR4 antagonist nanoparticles
Besides PCX and PCQ, other CXCR4 targeted nanoparticles have also been
reported for RNAi cancer therapy. These nanoparticles were typically formed by the
physical addition of small molecular CXCR4 inhibitor like AMD3100 to the formulation.
AMD3100 can act as both cancer targeting ligand for improved nanoparticles delivery
and CXCR4 antagonism for cancer therapy [43, 46, 61]. For example, the Chen’s group
developed a CXCR4-targeted lipid-based nanoparticles (NP) to specifically deliver
vascular endothelial growth factor (VEGF) siRNA as an antiangiogenic substance into
liver cancer. AMD3100 was added into the nanoparticles to serve as both a targeting
moiety and a sensitizer to antiangiogenic therapy. These AMD3100-modified NPs
efficiently delivered VEGF siRNAs into liver cancer and downregulated VEGF
expression in vitro and in vivo. The combination of CXCR4 inhibition by AMD3100 and
VEGF siRNA induced synergistic antiangiogenic effects and suppressed primary tumor
growth and distant metastasis in orthotopic liver cancer model [61].
1.5.2 CXCR4-silencing nanoparticles
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SiRNA silencing of CXCR4 also represents an additional approach to target
CXCR4/CXCL12 axis. Multiple studies reported the delivery of CXCR4 siRNA using
nanoparticles [36, 63, 95-97]. For example, a lipid-modified polymeric carrier was
developed for CXCR4 siRNA delivery to acute myeloid leukemia (AML) cells. CXCR4
siRNA was successfully delivered to mononuclear cells derived from AML patients,
which resulted in significant CXCR4 silencing in tested samples. Decreasing CXCR4
expression via lipopolymer/siRNA nanocarriers was proven as a potential option for AML
therapy [63]. In another study, a fusion protein containing an anti-HER2 single-chain
antibody fragment was reported to deliver CXCR4 siRNA for HER2+ breast cancer
treatment. CXCR4 knockdown by siRNA effectively inhibited breast tumor growth and
metastasis both in vitro and in vivo [36].
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Figure 1.7. Chloroquine containing polycation for improving endosome escape of
delivered miRNA and inhibiting cell migration. (Reprinted with permission from Ref [22])
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1.6 Summary
The benefits of both CXCR4 inhibition and siRNA/miRNA delivery for improved
cancer therapies are clearly established. CXCR4-targeted nanocarriers are greatly
potential nanomedicines to deliver functional siRNA/miRNA for combination therapy. The
dual function polymeric CXCR4 antagonists simultaneously block the CXCR4/CXCL12
axis and deliver functional siRNA and miRNA to cancer cells, which normally result in
the inhibition of primary tumor growth and reduction of metastasis. Using CQ as an
alternative CXCR4 inhibitor allows to advantageously combine CXCR4 antagonism with
endosomolytic properties of CQ to enhance cytoplasmic delivery of siRNA and miRNA.
Besides the PCX and PCQ polymers, CXCR4 inhibitors or CXCR4 siRNA can also be
encapsulated into suitable nanocarriers for CXCR4 inhibition. These CXCR4 targeted
nanomedicines carrying functional siRNA/miRNA represent a promising choice for
combination cancer therapy especially metastasis inhibition.

27

Chapter 2 - Delivery of miR-200c mimic with poly(amido amine) CXCR4
antagonists for combined inhibition of cholangiocarcinoma cell invasiveness
Please note that part of the content of this chapter was published in Molecular
Pharmaceutics (Xie, Wehrkamp et al, 2016) [59]. As the first author, I performed all the
work in the paper. Prof. Oupický and co-authors helped to interpret the data and prepare
the manuscript. All the authors agreed with including their work in this dissertation.
2.1 Introduction
Cholangiocarcinoma is a malignant neoplasm of the biliary duct system.
Intrahepatic cholangiocarcinoma (ICC) arises from the epithelial cells of the intrahepatic
bile ducts [98, 99]. ICC is the second most common primary liver malignancy after
hepatocellular carcinoma and accounts for 10-25% of all primary hepatic malignancies.
The incidence rate of ICC has increased worldwide over the past decade. Despite
advances in surgical techniques, chemotherapy and radiotherapy, 5-year survival rate of
patients after diagnosis has not increased and remains at ~10% [100]. The ICC is highly
fatal mainly due to early invasion and widespread metastasis and the lack of effective
therapeutic options [101, 102]. Among others, therapeutic strategies that focus on
addressing the invasive character of ICC promise to improve the treatment outcomes.
MicroRNAs are noncoding RNAs with about 22 nucleotides in length. MicroRNA
is involved in the regulation of gene expression at a post-transcriptional level through
binding to the target sites of messenger RNAs. Growing number of studies confirm the
important role of microRNAs in formation and progression of various human cancers,
including ICC [103-109]. Recent evidence suggests that migration, invasion and
metastasis of ICC are regulated by multiple microRNAs, including miR-21[110], miR200c [73], and miR-214 [111]. For example, increasing levels of miR-200c decreased the
extent of the epithelial-to-mesenchymal transition (EMT) and inhibited cell migration and
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invasion in ICC cells [73]. Despite the potential of microRNA for cancer therapy, the
clinical translation of therapeutic microRNA is hindered by a lack of efficient delivery
systems [112, 113]. The negative charge and low molecular weight of microRNAs make
them suitable for formulation in nanoscale delivery systems, thus enabling their use in
clinical cancer therapy [114]. Polycations are widely used as miRNA carriers for gene
therapy in cancer [3, 115]. For example, cationic polyurethanes-short branch PEI
delivered miR-145 to xenograft tumors to reduce tumor growth and metastasis [116].
The chemokine receptor CXCR4 plays a crucial role in metastatic spread of
multiple types of cancer, including ICC, making it a potential therapeutic target [117-121].
Stromal cell-derived factor-1 (SDF-1, CXCL12) is the only chemokine ligand for the
CXCR4 receptor and is highly expressed in the liver. Binding of SDF-1 to CXCR4 can
activate several intracellular signaling transduction pathways that regulate migration and
invasion of cancer cells. CXCR4 facilitates the metastatic spread of the primary tumor to
sites where SDF-1 is highly expressed. Numerous studies have shown that blocking
CXCR4 activation with CXCR4 antagonists inhibits metastasis of multiple tumor types
[122-124]. The anti-metastatic effect of CXCR4 inhibition can be enhanced by
simultaneous use of nucleic acids that target additional pathways involved in cancer cell
migration and invasion. This was demonstrated in a recent study which combined
inhibition of the CXCR4 axis with siRNA knockdown of Lipocalin-2 (Lcn2) as a way of
synergistically reducing migration in metastatic human breast cancer cells [125].
We have recently developed a series of polymeric CXCR4 antagonists (PCX)
capable of delivering various types of nucleic acids, including DNA and siRNA [126-129].
The developed PCX polymers effectively block cancer cell invasion by inhibiting the
CXCR4/SDF1 axis, while at the same time, deliver nucleic acids into the cancer cells for
improved anticancer effect. The PCX polymers were synthesized from either FDA-
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approved CXCR4 antagonist AMD3100 (Scheme 2.1A) or novel CXCR4-inhibiting
monocyclam inhibitors (Scheme 2.1B). In the present study, we hypothesized that
combining the CXCR4 axis blockade with the action of miR-200c mimic would enhance
the inhibition of the migration of metastatic ICC cells more efficiently than either one of
these treatments alone. We expected that in addition to CXCR4 antagonism, the PCX
could deliver miR-200c into ICC cells and inhibit EMT by inhibiting zinc finger E-boxbinding homeobox 1 (ZEB1) expression, thus enhancing the inhibitory effect on cancer
cell migration and invasion (Scheme 2.1C). The ability of the combined PCX/miR-200c
treatment to obstruct two migratory pathways represents a promising antimetastatic
strategy in ICC.

Scheme 2.1. Chemical structure of (A) AMD3100 (Plerixafor) and (B) PCX. (C)
Mechanism of action of PCX/miR-200c polyplexes.

30

2.2 Materials and methods
2.2.1 Materials
Dulbecco’s modified Eagle medium (DMEM), Dulbecco’s phosphate buffered
saline (PBS), and fetal bovine serum (FBS) were from ThermoScientific (Waltham, MA).
Cell culture inserts (for 24-well plates, 8.0 µm pores, Translucent PET Membrane, cat#
353097) were purchased from BD Biosciences (Billerica, MA). Human SDF-1α was from
Shenandoah Biotechnology, Inc. (Warwick, PA). Oligofectamine was from Invitrogen
(Carlsbad, USA) and used as suggested by the supplier. BLOCK-iT™ Fluorescent Oligo
(FITC-Oligo) was supplied by ThermoFisher Scientific. MicroRNA-200c mimic (mature
microRNA sequence: 5′-UAAUACUGCCGGGUAAUGAUGGA-3′), and negative control
miR-NC mimic (mature microRNA sequence: 5′-UCACAACCUCCUAGAAAGAGUAGA 3′) were purchased from Dharmacon (Lafayette, CO). Polymeric CXCR4 antagonist
(PCX, Mw = 5230, Mw/Mn = 1.27) was synthesized and characterized as previously
described [127]. All other reagents were from Fisher Scientific and used as received
unless otherwise noted.
2.2.2 Cell culture
Human malignant intrahepatic cholangiocarcinoma HuCCT1 cell line was kindly
provided by Dr. Gregory Gores, Mayo Clinic, Rochester MN. The cell line was derived
previously from the malignant ascites fluid from a 56-year-old male patient with
intrahepatic cholangiocarcinoma [130]. HuCCT1 cells were grown in high glucose
DMEM supplemented with 10% FBS, penicillin (100 U/mL), streptomycin (100 µg/mL),
G418 (50 µg/mL), and insulin (0.5 µg/mL) at 37°C with 5% CO2 in a humidified chamber
[130, 131].
2.2.3 Surface expression of CXCR4
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HuCCT1 cells were detached with enzyme-free Cell Dissociation Buffer (Thermo
Scientific) and suspended in a staining buffer. Cells were stained live with
allophycocyanin (APC)-conjugated anti-CXCR4 antibody (Abcam, USA) for 1 h at 4 °C.
Isotype-matched negative control was used in the panel of mAb to assess background
fluorescence intensity. Samples were analyzed on a BD FACSCalibur flow cytometer
(BD Bioscience, Bedford, MA). The results were processed using FlowJo software (Tree
Star Inc., Ashland, OR).
2.2.4 Preparation and physicochemical characterization of PCX/microRNA
polyplexes
The ability of PCX to condense microRNA was determined by electrophoresis in
a 2% agarose gel containing 0.5 μg/mL ethidium bromide (EtBr). PCX/microRNA
polyplexes were formed by adding predetermined volume of PCX to a microRNA
solution (20 μM in 10 mM HEPES pH 7.4) to achieve the desired w/w ratio and
vigorously vortexed for 10 s. Polyplexes were then incubated at room temperature for 30
min before further use. Polyplexes prepared at different PCX-to-microRNA weight ratios
were loaded (20 μL of the sample containing 1.0 μg of microRNA) and run for 30 min at
100 V in 0.5×Tris/Borate/EDTA buffer. The gels were visualized under UV illumination on
a KODAK Gel Logic 100 imaging system. MicroRNA release from polyplexes was
analyzed by heparin displacement assay. The polyplexes were prepared at a w/w ratio
of 12 and incubated with increasing concentrations of heparin for 30 min at room
temperature. The samples (20 μL of the sample containing 0.5 μg of microRNA) were
then analyzed by agarose gel electrophoresis. Hydrodynamic diameter and zeta
potential of the polyplexes were determined by dynamic light scattering (DLS) using a
ZEN3600 Zetasizer Nano-ZS (Malvern Instruments Ltd., Massachusetts,
United States).
2.2.5 Cellular uptake and intracellular trafficking of polyplexes
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Flow cytometry analysis was used to study the cellular uptake of polyplexes.
HuCCT1 cells (5 × 104) were seeded in 24-well plates and cultured to reach about 50%
confluence. The cells were incubated at 37 °C with PCX/FITC-Oligo polyplexes at a
FITC-Oligo concentration of 200 nM for 4 h. The cells were then trypsinized, washed
with cold PBS, filtered through 35 μm nylon mesh, and subjected to analysis using a BD
FACSCalibur flow cytometer (BD Bioscience, Bedford, MA). The results were processed
using FlowJo software. Intracellular localization was observed seperately by confocal
laser scanning microscope. Cells were cultured on 20 mm glass-bottom cell culture dish
(Nest) at 1 × 105 cells/dish. After 24 h, the medium was exchanged with fresh medium
and PCX/FITC-Oligo polyplexes were added (200 nM FITC-Oligo). After incubation for 4
h, the cells were washed twice with PBS and stained with LysoTracker® Red DND-99
(Life Technology, USA) for 30 min, fixed with 4% paraformaldehyde for 10 min, and
stained with Hoechst 33258 for 10 min. The cells were rinsed 3 times with PBS and
visualized by LSM 710 Laser Scanning Microscope (Zeiss, Jena, Germany).
2.2.6 Quantitative real-time PCR (qRT-PCR)
The expression levels of miR-200c were evaluated by TaqMan qRT-PCR.
mirVana™ miRNA Isolation Kit (Ambion™, USA) was used for total RNA extraction from
cultured cells. 10 ng of total RNA was converted into cDNA using specific primers for
miR-200c (or the internal control Z30 (Applied Biosystems, Foster City, CA)) and the
TaqMan microRNA reverse transcription kit (Applied Biosystems). qRT-PCR was
performed using TaqMan Universal Master Mix II, No AmpErase UNG (2×) and specific
primers for miR-200c or Z30 (Applied Biosystems, Foster City, CA) on a Rotor-Gene Q
instrument (QIAGEN) according to the manufacturer’s instructions. MicroRNA
expression levels were expressed relative to the internal control according to the
comparative threshold cycle (Ct) method.
2.2.7 Western blot
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Cultured cells were lysed with RIPA Lysis buffer by incubation on ice for 10 min.
After centrifugation at 12,000 g for 10 min, the supernatants were collected and the
concentrations of proteins were quantified by the BCA protein assay kit (Promega, USA).
The protein samples were denatured by boiling for 5 min, loaded onto 10% SDS-PAGE
gel for electrophoresis (at 120 V for 2 h), and then transferred (at 300 mA for 1 h) to a
nitrocellulose membrane. After blocking with 5% non-fat dried milk at room temperature
for 1 h, the membrane was incubated overnight at 4 °C with ZEB1 rabbit monoclonal
antibody (Cell Signaling Technology, USA), then washed and incubated with the
secondary anti-rabbit IgG HRP-linked Antibody (Cell Signaling Technology, USA) for 1 h.
Finally, membranes were again washed and visualized using Pierce™ ECL Western
Blotting Substrate (Thermo Scientific, USA). Quantification of western blot bands was
performed using ImageJ software (National Institutes of Health, Bethesda, MD), and the
data were expressed as relative ZEB1 level compared with untreated cells.
2.2.8 Wound healing assay
HuCCT1 cells (2 × 105) were seeded into 6-well plates and cultured in complete
DMEM to reach about 50% confluence. Cells were then treated with PCX/miR-200c
polyplexes (w/w=12) containing 200 nM miR-200c for 4 h. The polyplex solution was
then removed and replaced with fresh medium. Oligofectamine/microRNA lipoplexes
were transfected into cells according to the manufacturer’s protocol. When the cells
reached confluence at 48 h post-transfection, an artificial wound was created in the
monolayer with a sterile plastic 1 mL micropipette tip. Next, the cell monolayers were
rinsed gently with PBS and further incubated. Pictures of the wounds were taken using a
phase-contrast microscope at different time points.
2.2.9 Transwell migration assay
HuCCT1 cells (2 × 105) were seeded into 6-well plates and cultured in complete
DMEM to reach 50% confluence. The cultured cells were subsequently treated with
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PBS, Oligofectamine/miR-NC, Oligofectamine/miR-200c, PCX/miR-NC, PCX/miR-200c
at microRNA concentration of 200 nM. After 48 h incubation, the cells were trypsinized
and suspended in medium without serum. Subsequently, 5 × 104 cells were seeded in
the top chambers in 300 μL of serum-free medium and 500 μL of complete medium
containing 10% FBS was added to the lower transwell chambers. After 24 h, the nonmigrated cells in the top chamber were removed with a cotton swab. The migrated cells
were then fixed and stained by dipping the inserts into staining Diff-Quick solution. The
images were taken by EVOS xl microscope. Three 20× visual fields were randomly
selected for each insert and each group was conducted in triplicate.
2.2.10 Cytotoxicity
Toxicity of the polyplexes was evaluated by Cell Titer Blue assay in HuCCT1
cells. The cells were plated in 96-well microplates at a density of 5,000 cells/well. After
24 h, the cultured cells were treated with PBS, Oligofectamine/miR-NC,
Oligofectamine/miR-200c, PCX/miR-NC, PCX/miR-200c at microRNA concentration of
200 nM. After further 48 h incubation, the medium was removed and replaced with a
mixture of 100 μL serum-free media and 20 μL of CellTiter-Blue reagent (CellTiter-Blue®
Cell Viability Assay, Promega). After 2 h incubation, the Fluorescence (560/590nm) was
measured on Synergy 2 Microplate Reader (BioTek, VT). The relative cell viability (%)
was calculated as [Fluorescence]sample/[Fluorescence]untreated × 100%.
2.2.11 Statistical analysis
Data are presented as the mean ± SD. The statistical significance was
determined using ANOVA followed by Bonferroni post hoc correction with p < 0.05 as
the minimal level of significance.
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2.3 Results and discussion
2.3.1 CXCR4 expression and CXCR4-mediated migration in HuCCT1 cells

Surface expression of CXCR4 in HuCCT1 cells was confirmed by flow cytometry
(Figure 2.1A). Over 36% of the HuCCT1 cells were CXCR4-positive with enhanced
fluorescence intensity per cell. We then assessed the involvement of CXCR4 in the
migration of the cells. A migration assay was performed to test whether SDF-1 induced
migration of HuCCT1 cells and whether this migration could be inhibited by CXCR4
antagonists. As shown in Figure 2.1B, substantially increased migration across the
transwell insert membrane was observed in HuCCT1 cells stimulated with the
chemoattractant SDF-1. In agreement with previous reports in other cholangiocarcinoma
cells, the cell migration could be significantly inhibited by CXCR4 antagonist AMD3100
[119].
2.3.2 Preparation and physicochemical characterization of PCX/microRNA
polyplexes
The ability of PCX to form polyplexes with microRNA was first evaluated by
agarose gel electrophoresis. As shown in Figure 2.2A, PCX was able to fully condense
microRNA above a PCX/microRNA (w/w) ratio of 2. PCX condensation of the microRNA
was observed already at low w/w ratios (0.5-1) as indicated by the smear of the ethidium
bromide stained microRNA and as strong fluorescence in the starting well of the gel. At
higher PCX/microRNA w/w ratios (above 2), condensed microRNA was completely
protected from ethidium bromide binding and no fluorescence signal was observed. The
stability of the PCX/microRNA polyplexes against dissociation was then determined by
heparin displacement assay (Figure 2.2B). For PCX/microRNA polyplexes prepared at
w/w 12, heparin was able to dissociate the polyplexes and release microRNA above 200
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μg/mL heparin. Hydrodynamic size and zeta-potential of PCX/microRNA polyplexes
prepared at various w/w ratios were measured by DLS. Polyplexes with all the tested
w/w ratios exhibited size in a narrow range from 160 to 180 nm with polydispersity
indexes <0.2 (Figure 2.2C). The size distribution of polyplexes showed a logtransformed normal distribution (Figure 2.2D). As expected, increased w/w ratio used in
the preparation of the polyplexes resulted in an increase of the zeta potential (Figure
2.2E).
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Figure 2.1. Characterization of the CXCR4 status of HuCCT1 cells. (A) Flow cytometric
histograms show CXCR4 expression on HuCCT1 cell surface. The percent of CXCR4positive cells and mean fluorescence intensity were analyzed using FlowJo software. (B)
Inhibition of CXCR4-mediated cell migration. HuCCT1 cells were treated with AMD3100
(300 nM) and allowed to migrate through transwell membranes upon stimulation with
SDF-1 for 24 h. Three 20× imaging areas were randomly selected for each insert and
each group was conducted in triplicate. Data are shown as mean ± SD (n = 3). ***p <
0.001.
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Figure 2.2. Physicochemical characterization of PCX/microRNA polyplexes. (A)
MicroRNA condensation by PCX in 10 mM HEPES buffer (pH 7.4) using agarose gel
electrophoresis. (B) Heparin induced microRNA release from the polyplexes. Polyplexes
were prepared at w/w 12 and incubated with increasing concentrations of heparin. (C)
Hydrodynamic size of PCX/microRNA polyplexes. (D) Size distribution of
PCX/microRNA (w/w=12). (E) Zeta-potential of PCX/microRNA polyplexes. (F) Zetapotential of PCX/microRNA (w/w=12) as determined by dynamic light scattering. Data
shown as mean ± SD (n = 3).
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2.3.3 Cellular uptake and intracellular trafficking
To study the cellular uptake and intracellular trafficking of the polyplexes, we
used a fluorescently labeled FITC-Oligo (200 nM) instead of microRNA in the
preparation of the polyplexes. HuCCT1 cells were treated with PCX/FITC-Oligo for 4 h
before flow cytometry analysis. As shown in Figure 2.3A, PCX polyplexes exhibited
significant cellular uptake in HuCCT1 cells as indicated by the enhanced fluorescence
intensity when compared with untreated cells or cells treated with free FITC-Oligo.
Increasing the w/w ratios in preparation of the polyplexes resulted in enhanced cell
uptake, both in terms of the mean fluorescence intensity per cell (Figure 2.3B) and the
percentage of cells that have taken up the polyplexes (Figure 2.3C). PCX polyplexes
prepared at highest tested w/w = 12 showed the highest cell uptake and were thus
selected for subsequent studies.
We further evaluated the intracellular trafficking of the PCX polyplexes using
confocal microscopy. PCX/FITC-Oligo polyplexes (green) prepared at w/w 12 were
incubated with the cells for 4 h. Lysosomes were stained with Lysotracker Red (red) and
cell nuclei were stained with Hoechst 33258 (blue). As shown in Figure 2.3D, the
fluorescence of the FITC-Oligo was distributed mainly in the cytoplasm and no FITCOligo signal was found in the cell nucleus. Limited extent of the co-localization of the
FITC-Oligo signal with the LysoTracker signal in lysosomes (red) indicated efficient
endosomal escape of the PCX polyplexes.
2.3.4 MicroRNA transfection
miR-200c and its negative control miR-NC were used to evaluate the microRNA
transfection efficiency of the PCX polyplexes. The levels of miR-200c in HuCCT1 cells
were measured using TaqMan qRT-PCR (Figure 2.4). PCX polyplexes exhibited high
microRNA transfection efficiency, as indicated by a nearly 9,500-fold increase in
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intracellular miR-200c levels when polyplexes prepared at w/w=12 were used. Similar to
the results of the cell uptake experiment (Figure 2.3), increasing the w/w ratio in
preparing the polyplexes resulted in significantly enhanced transfection efficiency.
Having confirmed the ability of PCX to effectively deliver miR-200c to the HuCCT1
cells, we then evaluated the effect of the delivered miR-200c on the target intracellular
pathway. We used Western blot to analyze the cellular levels of one of the downstream
targets of miR-200c, namely the zinc finger E-box-binding homeobox 1 (ZEB1). ZEB1 is
an inducer of the epithelial-to-mesenchymal transition (EMT) in cancer cells and its
overexpression is associated with cancer cell migration and invasion [73, 132, 133]. As
shown in Figure 2.5, delivery of miR-200c using PCX polyplexes resulted in a significant
decrease (46.3%) in cellular ZEB1 protein levels in the HuCCT1 cells when compared with
the control PCX/miR-NC polyplexes. This finding confirms that the miR-200c was
delivered by the PCX polyplexes into the cytoplasm and efficiently released in its active
state to successfully downregulate the target ZEB1 protein.
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Figure 2.3. Cellular uptake and intracellular trafficking of PCX polyplexes. (A) Overlayed
histogram of flow cytometry analysis of cells treated with PCX/FITC-Oligo polyplexes at
various w/w ratio (200 nM FITC-Oligo). Quantification of cellular uptake is shown by (B)
mean fluorescence intensity (MFI) and (C) % cell uptake. Data are shown as mean ± SD
(n = 3). (D) Intracellular trafficking of PCX/FITC-Oligo in HuCCT1 cells by CLSM after 4 h
incubation.
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Figure 2.4. Transfection activity of PCX/microRNA polyplexes. miR-200c level was
detected by TaqMan qRT-PCR in HuCCT1 cells. Data are shown as mean ± SD (n = 3).
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Figure 2.5. Effect of miR-200c delivery on the expression of ZEB1 protein. Quantification
of Western blot bands was performed using ImageJ software and the data are expressed
as relative ZEB1 levels relative to untreated cells.
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2.3.5 Cell migration
After confirming the ability of the PCX polyplexes to deliver functional microRNA
to the human cholangiocarcinoma cells, we evaluated the cooperative effect of the
inhibition of ZEB1 by miR-200c and CXCR4 inhibition by PCX on the migration of the
cells. Before proceeding, we first confirmed that the selected polyplex formulations have
no significant adverse effect on cell viability that could negatively affect their migratory
properties. As shown in Figure 2.6, the cells treated with all the PCX polyplexes as well
as the control Oligofectamine lipoplexes exhibited nearly 100% viability after 48 h
incubation, indicating no adverse effects on cell proliferation. The migration of the cancer
cells was then assessed using a wound healing assay and a transwell cell migration
assay.
Wound healing assay was conducted to study the combined inhibitory activity of
PCX/miR-200c polyplexes on migration of HuCCT1 cells. The cells were treated with
PCX/miR-200c polyplexes and an artificial wound was created 48 h post-transfection.
The healing status of the wound, which represents the extent of cell migration, was
measured after 24 and 48 h. As shown in Figure 2.7, the untreated (PBS) wound
reached nearly complete closure after 48 h. The cells treated with control PCX/miR-NC
exhibited significant inhibition of wound healing (56% closure) after 48 h, which is
consistent with the CXCR4 antagonistic activity of PCX and its effect on cell migration.
The combination treatment with PCX/miR-200c polyplexes further enhanced the extent
of inhibition (40% closure) due to the cooperative activity of the CXCR4 antagonism of
PCX and the effect of miR-200c on ZEB1. ZEB1 has previously been implicated in the
migration-inhibitory effect of miR-200c, suggesting ZEB1 may be a functional mediator of
this effect in HuCCT1 cells. As expected, no inhibition of wound healing was observed
when the control miR-NC was delivered using Oligofectamine. When used to deliver
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miR-200c, Oligofectamine lipoplexes exhibited partial inhibition of wound closure (61%
closure).
To further confirm the cooperative activity of PCX and miR-200c on the inhibition
of cancer cell migration, transwell assay was also performed. HuCCT1 cells were
transfected with PCX/miR-200c polyplexes as before and 10% FBS was applied to the
lower chamber as the chemoattractant to induce the transwell cell migration. As shown
in Figure 2.8, the migration of HuCCT1 cells was significantly inhibited following
treatment with control Oligofectamine/miR-200c. Treatment with another control,
PCX/miR-NC, resulted in marked migration inhibition due to the CXCR4 antagonism of
PCX. Combined treatment with PCX/miR-200c achieved the highest inhibition level of
cell migration (~81%) among all the tested formulations, confirming the cooperative
effect of PCX and miR-200c.
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Figure 2.6. Cell viability was measured using Cell Titer Blue assay in HuCCT1 cells.
HuCCT1 cells were treated with PCX polyplexes or control Oligofectamine complexes for
48 h. Data are shown as mean ± SD (n = 3).
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Figure 2.7. Inhibition of wound healing. Cells were treated with formulations for 48 h. Then
an artificial wound was created in the monolayer with a 1 mL pipette tip. 4× imaging areas
of the wounds were taken using a microscope at different time points. Wound closure was
expressed as % initial wound size (mean ± SD; n = 3) (Scale bar = 1000 μm). Data are
shown as mean ± SD (n = 3). ***p < 0.001.
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Figure 2.8. Inhibition of cancer cell migration. HuCCT1 cells were transfected with
Oligofectamine lipoplexes or PCX polyplexes for 48 h and then allowed to migrate through
Transwell upon stimulation with 10% FBS for 24 h. Three 20× imaging areas were
randomly selected for each insert and each group was conducted in triplicate. Data are
shown as mean ± SD (n = 3). ***p < 0.001.
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2.4 Conclusion
In this study, CXCR4-inhibiting polycation (PCX) was used to deliver miR-200c
mimic with the goal of improving the inhibition of cholangiocarcinoma cell migration. The
results show that PCX can inhibit the cancer cell migration due to its CXCR4
antagonism. The ability of PCX to form polyplexes with nucleic acids was used for
simultaneous delivery of miR-200c mimic into cells. The delivery of miR-200c resulted in
reduced expression of the EMT inducer ZEB1. The combination treatment consisting of
PCX and miR-200c resulted in cooperative anti-migration activity, most likely by coupling
the CXCR4 axis blockade with EMT inhibition in the cholangiocarcinoma cells. Our
results provide a promising strategy for a combination therapy involving multiple
migration pathways in metastatic cholangiocarcinoma.
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Chapter 3 – Cholangiocarcinoma therapy with nanoparticles that combine
downregulation of microRNA-210 with inhibition of cancer cell invasiveness
Please note that part of the content of this chapter was published in Theranostics
(Xie, Wang et al, 2018) [134]. As the first author, I performed all the experiments in the
paper except the synthesis of PCX by Yu Hang and Lee Jaramillo. Prof. Oupický and coauthors helped to interpret the data and prepare the manuscript. All the authors agreed
with including their work in this dissertation.
3.1 Introduction
Cholangiocarcinoma (CCA) is an aggressive cancer of the biliary duct system.
CCA is a deadly disease with dismal prognosis as evident from its low 10% five-year
survival rates. Surgery is the only curative option for CCA. However, over 70% of CCA
patients are diagnosed at late stage and not eligible for surgical resection [135, 136].
The high mortality of CCA is attributed to the early invasion and widespread metastasis.
No effective treatment options exist for metastatic CCA [137]. Advanced CCA is
currently treated with a combination of gemcitabine (GEM) and cisplatin (CDDP).
Unfortunately, the therapeutic outcome of systemic GEM/CDDP treatment is poor due to
drug resistance [138, 139]. These therapeutic challenges highlight the urgent need to
develop new therapeutics to inhibit metastasis and reverse drug resistance in CCA
therapy.
CXCR4 overexpression has been found in more than 20 major human cancer
types, including CCA [23, 140]. The upregulation of CXCR4 is highly dependent on
multiple transcription factors, growth factors, and hypoxia-inducible factors. The hypoxic
tumor microenvironment can induce CXCR4 based on activation of the hypoxia-inducible
factor-1α (HIF1α) and transcript stabilization [89]. The binding of CXCL12 to CXCR4
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activates intracellular signaling to promote migration and invasion of cancer cells.
CXCR4 then facilitates the metastasis of the primary tumor cells to these sites where
CXCL12 is highly expressed [11, 141]. Inhibition of the signaling pathway with CXCR4
antagonists decreases the motility and invasion of CCA cells [119, 142]. Inhibition of
CXCR4 also can reverse drug resistance and improve chemotherapy, as documented by
chemosensitizing effect of a CXCR4 antagonist AMD3100 to GEM in human CCA cells
[17, 143]. Several studies reported that CXCR4 inhibition reduced the stemness of
cancer cells to overcome drug resistance [144, 145]. Current evidence strongly supports
the potential of CXCR4 inhibition to reverse drug resistance and inhibit metastasis in
CCA.
MiRNAs can act as tumor suppressors or oncogenes and play an important role
in tumorigenesis, tumor growth, angiogenesis, and metastasis [146]. A growing number
of studies confirm the important role of miR-25, miR-34a, and let-7c in CCA formation
and progression [106, 107, 147, 148]. Recent evidence already suggests that miRNA
therapy can inhibit CCA growth, metastasis, and improve survival in animal models [149151]. Hypoxia in CCA induces the upregulation of miR-210, which helps the cancer cells
to adapt to the hypoxic microenvironment through multiple biological pathways [152,
153]. Oncogenic activity of miR-210 is responsible for cell proliferation, apoptosis,
metastasis, DNA repair, cell metabolism, and antitumor drug resistance [93, 154, 155].
Hence, inhibition of miR-210 provides a promising target for the treatment of CCA.
Despite the great potential of miRNAs in metastatic cancer, their clinical
translation has been limited by a lack of efficient and safe systemic delivery systems
[112, 156]. We have reported on a series of polymeric CXCR4 antagonists (PCX)
capable of delivering miRNA, siRNA, and DNA [19, 59, 60, 157]. PCX simultaneously
inhibit cancer cell invasion by CXCR4 axis blockade and deliver nucleic acids into
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various cancer cells for improved anticancer effect. PCX were synthesized from
AMD3100 and modified with cholesterol to improve the stability of their nanoparticles for
better systemic delivery [21, 58]. Due to the key roles of CXCR4 and miR-210 in CCA,
we hypothesized that combining inhibition of CXCR4 by PCX and inhibition of hypoxiainducible miR-210 would cooperatively enhance the therapy of CCA through reducing
invasiveness, inducing cell killing and overcoming drug resistance (Scheme 3.1). To test
this hypothesis, we used PCX modified with cholesterol to prepare PCX/anti-miR-210
nanoparticles and to evaluate their delivery activity and anticancer efficacy in CCA both
in vitro and in vivo.

Scheme 3.1. Proposed mechanism of action of PCX/anti-miR-210 nanoparticles.
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3.2 Materials and methods
3.2.1 Materials
Cholesterol-modified polymeric CXCR4 inhibitors PCX (Mw = 16.7 kDa, Mw/Mn =
1.9, cholesterol wt% =16.8%) was synthesized and characterized as previously
described [58]. Succinimidyl ester of Alexa Fluor® 647 carboxylic acid was from Life
Technologies (Eugene, OR). AlexaFluor 647 labeled PCX polymers (AF647-PCX) were
produced according to manufacturer’s instructions and purified by dialysis to remove
unreacted dye. AMD3100 was from Biochempartner (Shanghai, China). Dulbecco’s
modified Eagle medium (DMEM), Dulbecco’s phosphate buffered saline (PBS), and fetal
bovine serum (FBS) were from Thermo Scientific (Waltham, MA). Hsa-miR-210-3pHairpin Inhibitor (anti-miR-210, mature miRNA sequence: 5′CUGUGCGUGUGACAGCGGCUGA-3′), negative control miR-NC inhibitor (anti-miRNC, mature miRNA sequence: 5′-UCACAACCUCCUAGAAAGAGUAGA-3′), and
carboxyfluorescein (FAM) labeled FAM-anti-miRNA were purchased from Dharmacon
(Lafayette, CO). Cell culture inserts (for 24-well plates, 8.0 μm pores, Translucent PET
Membrane, cat# 353097) were purchased from BD Biosciences (Billerica, MA). Realtime (RT)-PCR primers were purchased from Invitrogen (Carlsbad, CA). Allophycocyanin
(APC) mouse anti-human CXCR4 antibody and APC mouse lgG2a, ĸ isotype controls
were from BD Biosciences (San Jose, CA). All other reagents were from Fisher Scientific
and used as received unless otherwise noted.
3.2.2 Cell culture
Human malignant cholangiocarcinoma Mz-ChA-1 cell line was kindly provided by
Dr. Gregory Gores, Mayo Clinic, Rochester, MN. Mz-ChA-1 cells were grown in highglucose DMEM supplemented with 10% FBS, penicillin (100 U/mL), streptomycin (100

54

μg/mL), G418 (50 μg/mL), and insulin (0.5 μg/mL) at 37 °C with 5% CO2 in a humidified
chamber. To induce hypoxia, cells were incubated in an atmosphere of 2% O2, 5% CO2,
and 93% N2 at 37 °C.
3.2.3 Cellular surface expression of CXCR4
Mz-ChA-1 cells were detached with enzyme-free Cell Dissociation Buffer
(Thermo Scientific) and suspended in a staining buffer. Cells were stained live with
allophycocyanin (APC)-conjugated anti-CXCR4 antibody for 1 h at 4 °C. Isotype
matched negative control was used in the panel of mAb to assess background
fluorescence intensity. Samples were analyzed on a BD FACS Calibur flow cytometer
(BD Bioscience, Bedford, MA). The results were processed using FlowJo software (Tree
Star Inc., Ashland, OR).
3.2.4 Analysis of pERK signaling by Western blot
Mz-Cha-1 cells were treated with AMD3100 (300 nM), PCX (3 μg/mL) for 4 h
followed by 20 min incubation with SDF-1 (100 ng/mL). Then, cells were lysed by RIPA
Lysis buffer. After centrifugation at 12,000 g for 10 min, the supernatants were collected
and the concentrations of proteins were quantified by the BCA protein assay kit
(Promega, USA). The protein samples were denatured by boiling for 5 min, loaded onto
10% SDS-PAGE gel for electrophoresis (at 120 V for 2 h), and then transferred (at 300
mA for 1 h) to a nitrocellulose membrane. After blocking with 5% non-fat dried milk at
room temperature for 1 h, the membrane was incubated overnight at 4 °C with pERK
rabbit monoclonal antibody (Cell Signaling Technology, USA), then washed and
incubated with the secondary anti-rabbit IgG HRP-linked Antibody (Cell Signaling
Technology, USA) for 1 h. Finally, membranes were again washed and visualized using
Pierce™ ECL Western Blotting Substrate (Thermo Scientific, USA). Quantification of
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western blot bands was performed using ImageJ software (National Institutes of Health,
Bethesda, MD). GAPDH and Erk were used as housekeeping controls. Quantification of
Western blot bands was performed using ImageJ software.
3.2.5 FBS-induced transwell migration assay
Mz-ChA-1 cells (2 × 105) were seeded into 6-well plates and cultured in complete
DMEM medium. The cultured cells were subsequently treated with AMD3100 (300 nM)
or PCX (3 μg/mL). After 48 h of incubation, the cells were trypsinized and suspended in
medium without serum. Subsequently, 3 × 104 cells were seeded in the top chambers in
300 μL of serum-free medium and 500 μL of complete medium containing 10% FBS was
added to the lower transwell chambers. After 12 h, the nonmigrated cells in the top
chamber were removed with a cotton swab. The migrated cells were fixed in 100%
methanol and stained with 0.2% Crystal Violet solution for 10 min at room temperature.
The images were taken by EVOS xl microscope. Three 20× visual fields were randomly
selected for each insert, and each group was conducted in triplicate.
3.2.6 Phospholipid lysophosphatidic acid (LPA)-induced transwell migration assay
Mz-ChA-1 cells (2 × 105) were seeded into 6-well plates and cultured in complete
DMEM medium. The cultured cells were subsequently treated with AMD3100 (300 nM)
or PCX (3 μg/mL). After 48 h of incubation, the cells were trypsinized and suspended in
medium without serum. Subsequently, 6 × 104 cells were seeded in the top chambers in
300 μL of serum-free medium and 500 μL of serum-free medium containing LPA (20 µM)
was added to the lower transwell chambers. After 12 h, the nonmigrated cells in the top
chamber were removed with a cotton swab. The migrated cells were fixed in 100%
methanol and stained with 0.2% Crystal Violet solution for 10 min at room temperature.
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The images were taken by EVOS xl microscope. Three 20× visual fields were randomly
selected for each insert, and each group was conducted in triplicate.
3.2.7 Preparation and characterization of nanoparticles
PCX/anti-miRNA nanoparticles were prepared by adding predetermined volume
of PCX to an anti-miRNA solution (20 μM in 10 mM HEPES pH 7.4) to achieve the
desired w/w ratio and vigorously vortexed for 10 s. Nanoparticles were then incubated at
room temperature for 20 min before further use. The ability of PCX to condense antimiRNA was determined by electrophoresis in a 2% agarose gel containing 0.5 μg/mL
ethidium bromide (EtBr). Nanoparticles formed at various polycation-to-anti-miRNA
weight ratios were loaded (20 μL of the sample containing 0.5 μg of microRNA) and run
for 15 min at 100 V in 0.5 × Tris/Borate/EDTA buffer. The gels were visualized under UV
illumination with a KODAK Gel Logic 100 imaging system. Hydrodynamic diameter and
zeta potential of the nanoparticles were determined by dynamic light scattering (DLS)
using a ZEN3600 Zetasizer Nano-ZS (Malvern Instruments Ltd., Massachusetts, USA).
Morphology was observed under transmission electron microscopy (TEM, Tecnai G2
Spirit, FEI Company, USA) using NanoVan® negative staining (Nanoprobes, USA). AntimiRNA release from nanoparticles was analyzed by heparin displacement assay. The
nanoparticles (w/w = 2) were incubated with increasing concentrations of heparin for 30
min at room temperature. The samples (20 μL of the sample containing 0.5 μg of antimiRNA) were then analyzed by agarose gel electrophoresis. For the serum stability test,
free anti-miRNA solution and nanoparticles (w/w = 2) solution were incubated with FBS
(v:v = 1:1) at 37 °C, respectively. Each sample was collected at a specified time interval
(0.5, 1, 2, 4, 8, and 24 h) and analyzed by gel electrophoresis. Prior to gel
electrophoresis, nanoparticles solution was pre-treated with heparin to displace antimiRNA from the nanoparticles.
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3.2.8 Cellular uptake and intracellular trafficking of nanoparticles
Flow cytometry analysis was performed to study the cellular uptake of the
nanoparticles. Mz-ChA-1 cells (5 × 104) were seeded in 24-well plates. After 24 h
growth, the cells were incubated for 4 h with nanoparticles prepared with AF647-PCX
and FAM-anti-miRNA (w/w =2, 100 nM FAM-anti-miRNA). The cells were then
trypsinized, washed with cold PBS, and subjected to analysis using a BD FACS Calibur
flow cytometer (BD Bioscience, Bedford, MA). The results were processed using FlowJo
software. Intracellular localization of AF647-PCX/FAM-anti-miRNA was also observed by
confocal laser scanning microscopy. Cells were cultured on a 20 mm glass-bottom cell
culture dish (Nest) using 1 × 105 cells per dish. After 24 h, the medium was replaced with
fresh medium and AF647-PCX/FAM-anti-miRNA nanoparticles were added (100 nM
FAM-anti-miRNA). After incubation for 4 h, the cells were washed twice with PBS,
stained with Hoechst 33258 for 10 min. The cells were visualized using a LSM 800 Laser
Scanning Microscope (Zeiss, Jena, Germany). Moreover, to follow the endosomal
release of nanoparticles, AF647-PCX/anti-miRNA nanoparticles were incubated with
cells for 4 h. Then, the cells were washed twice with PBS and stained with LysoTracker
Red DND-99 (Life Technology, USA) for 30 min. Finally, the cells were rinsed three
times with PBS and visualized with confocal microscope.
3.2.9 Quantitative real-time polymerase chain reaction (qRT-PCR)
Cells were seeded in 12-well plates at 1 × 105 cells per well 24 h prior to
treatment. Then, the cells were incubated with the nanoparticles containing anti-miRNA
(100 nM) in 1 mL of medium for 48 h. The expression levels of miR-210 were evaluated
by TaqMan qRT-PCR. The mirVana miRNA Isolation Kit (Ambion, USA) was used for
total RNA extraction from cultured cells. 10 ng of total RNA was converted into cDNA
using specific primers for miR-210 (or the internal control Z30, Applied Biosystems,
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Foster City, CA) and the TaqMan microRNA reverse transcription kit (Applied
Biosystems). qRT-PCR was performed using TaqMan Universal Master Mix II, No
AmpErase UNG (2×) and specific primers for miR-210 or Z30 (Applied Biosystems,
Foster City, CA) on a Rotor-Gene Q instrument (QIAGEN) according to the
manufacturer’s instructions. MiRNA expression levels were expressed relative to the
internal control according to the comparative threshold cycle (Ct) method.
3.2.10 Apoptosis
Firstly, apoptosis was analyzed using the Annexin V-FITC/PI Apoptosis Detection
Kit (BioLegend, USA). Briefly, cells were seeded in 12-well plates at a density of 1 × 105
cells per well 24 h prior to treatment. The cells were incubated with the nanoparticles
containing anti-miRNA (100 nM) in 1 mL of medium for 48 h. The Annexin V-FITC
apoptosis detection was performed using flow cytometry in accordance with the
manufacturer’s protocol, and the data were processed using FlowJo. Apoptosis
percentage was also quantified by nuclear morphology and visualized by treatment with
the fluorescent DNA-binding dye, DAPI (4′, 6-diamidine-2′-phenylindole dihydrochloride).
Briefly, cells were stained with 2 μg/mL of DAPI for 30 minutes at 37 °C. Apoptotic nuclei
(condensed, fragmented) were counted and presented as a percent of total nuclei. At
least 100 cells were counted per well and experiments were performed in triplicate.
Caspase 3/7 activity was measured by enzymatic fluorophore release (Apo-One)
according to the manufacturer's protocol (Promega).
3.2.11 Cytotoxicity of polymers and nanoparticles
Cytotoxicity of PCX and nanoparticles was tested in Mz-ChA-1 cells by Cell Titer
Blue assay. Cells were plated in 96-well microplates at a density of 5000 cells/well. After
24 h, cells were incubated with the PCX for another 48 h prior to measuring cell viability.

59

Toxicity of the nanoparticles carrying anti-miRNA was also evaluated. Briefly, cells were
plated in 96-well microplates at a density of 5000 cells/well. After 24 h, cells were
incubated with the nanoparticles containing miRNA (100 nM) for another 48 h prior to
measuring cell viability. The medium was then removed and replaced with a mixture of
100 μL serum-free media and 20 μL of CellTiter-Blue reagent (CellTiter-Blue Cell
Viability Assay, Promega). After a 2 h incubation, fluorescence (560/590 nm) was
measured on a SpectraMax iD3 Multi-Mode Microplate Reader (Molecular Devices, CA).
The relative cell viability (%) was calculated as [I]treated/[I]untreated × 100%.
3.2.12 Colony formation
Cells were transfected with nanoparticles containing miRNA (100 nM) for 4 h.
Then, transfected cells were reseeded in 6-well plates (200 cells per plate). Cells were
allowed to grow for 14 days. Cells were fixed in 100% methanol and stained with 0.2%
Crystal Violet solution for 10 min. Finally, plates were washed with distilled water and
photographed. Number of colonies in each well were quantified.
3.2.13 Aldefluor activity
Cells were transfected with nanoparticles containing miRNA (100 nM) for 4 h and
then replaced with fresh medium for incubation for 48h. Then, Aldefluor kit (Stem Cell
Technologies, Durham, NC, USA) was used to analyze ALDH enzymatic activity
according to the manufacturer’s instructions. Cells were suspended in Aldefluor assay
buffer containing ALDH substrate (BODIPY-aminoacetaldehyde) and incubated for 30
min at 37 °C. As the negative control, cells were treated with 50 mM
diethylaminobenzaldehyde (DEAB) inhibitor before adding ALDH substrate. The cells
were subjected to analysis using a BD FACSCalibur flow cytometer (BD Bioscience,
Bedford, MA).
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3.2.14 Tumor spheroid formation
Cells were transfected with nanoparticles containing miRNA (100 nM) for 4 h and
then cells were dissociated and plated in ultralow attachment 6-well plates (Corning,
New York) at a density of 5000 viable cells per well. Cells were cultured in serum-free
DMEM/F12 medium containing 5 μg/mL insulin (Sigma-Aldrich, St. Louis, MO, USA),
0.4% bovine serum albumin (Sigma-Aldrich, St. Louis, MO, USA), 10 ng/mL basic
fibroblast growth factor (Invitrogen, Waltham, MA, USA), and 20 ng/mL human
recombinant epidermal growth factor (Invitrogen, Waltham, MA, USA) and observed
after 14 days.
3.2.15 Chemotherapy sensitization
Cell viability assay was performed to study the activity of nanoparticles to
sensitize cells to chemotherapy. Cells were seeded in 96-well microplates at a density of
5000 cells/well. After 24 h, cells were incubated with indicated concentrations of
gemcitabine/cisplatin (GEM/CDDP, w/w=10), PCX/anti-miR-NC (100 nM) plus
GEM/CDDP and PCX/anti-miR-210 (100 nM) plus GEM/CDDP, respectively. After
incubation for another 48 h, CellTiter-Blue assay were performed to measure cell
viability. The IC50 were calculated in GraphPad Prism using a built-in dose–response
analysis as the total drugs (Gemcitabine plus cisplatin) concentration that achieves 50%
growth inhibition relative to untreated cells (n = 3). Moreover, synergy calculations were
performed to study the combinational effects between PCX/anti-miR-210 and
GEM/CDDP. Briefly, cells were seeded in 96-well microplates at a density of 5000
cells/well. After 24 h, cells were incubated with indicated concentrations of
gemcitabine/cisplatin (GEM/CDDP, w/w=10), PCX/anti-miR-210 and PCX/anti-miR-210
plus GEM/CDDP, respectively. After incubation for another 48 h, CellTiter-Blue assay
were performed to measure cell viability. The data from cell viability assays were
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analyzed using Combenefit software (Cancer Research UK Cambridge Institute). The
"Mapped Surface" views (Bliss model) were selected as graphical outputs for the
synergy distribution.
3.2.16 CCA xenograft tumor model
All animal experiments followed a protocol approved by the University of
Nebraska Medical Center Institutional Animal Care and Use Committee. Animals were
placed in a facility accredited by the Association for Assessment and Accreditation of
Laboratory Animal Care upon arrival. Male athymic nu/nu mice (6 weeks) were
purchased from Charles River Laboratories. The xenograft tumor model was generated
by subcutaneous injection of 5 × 106 Mz-ChA-1 cells in 1:1 mixture of PBS/Matrigel (100
µL) into the flank region of the mouse. Tumor hypoxia was evaluated using pimonidazole
hydrochloride (60 mg/kg) given by intraperitoneal injection. The mice were sacrificed 30
min after the pimonidazole injection, the tumors were excised, and frozen tumor sections
were stained with FITC-Mab1 antibody using the Hypoxyprobe-1 Plus Kit (Hypoxyprobe
Inc., Burlington) and imaged with the confocal microscope.
3.2.17 Biodistribution
Xenograft tumor mice (~300 mm3) were injected with AF647-PCX/FAM-miRNA
nanoparticles (w/w=2, 2.4 mg/kg AF647-PCX, 1.2 mg/kg FAM-miRNA) through tail vein.
The mice were sacrificed 24 h post administration, and the tumors and major organs
were harvested and subjected to ex vivo fluorescence imaging using Xenogen IVIS 200
(Ex = 640 nm, Em = 680 nm). The fluorescence from each organ was analyzed by the
instrument software. Then, the isolated tumors were embedded in an OCT compound,
cut into 10 μm sections, stained with DAPI, and imaged with the confocal microscope.
3.2.18 In vivo therapeutics effect
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When the tumor sizes reached about 150-200 mm3 at days 10 post-tumor
inoculation, mice were randomly assigned to 5 groups (n = 5) and injected with PBS,
GEM/CDDP, PCX/anti-miR-NC, PCX/anti-miR-210 and PCX/anti-miR-210 +
GEM/CDDP, respectively. PCX/anti-miRNA (w/w=2, 2.4 mg/kg PCX, 1.2 mg/kg antimiRNA) were injected at days 11, 13, 15 and 17 through tail vein. GEM/CDDP (15 mg/kg
GEM, 1.5 mg/kg CDDP) were given at days 12 and 16 by intraperitoneal injection.
Tumor volume was monitored by measuring the perpendicular size of the tumors using
digital calipers. The estimated volume was calculated according to the following formula:
tumor volume (mm3) = 0.5 × length × width2. Body weight of the mice was also recorded.
On days 22, mice were sacrificed, and all tumor tissues and major organs were
harvested, fixed in 4% paraformaldehyde, sectioned, and stained with H&E. The
apoptosis of tumor cells was determined using the Caspase 3 immunohistochemical
staining according to the manufacturer's instructions. Blinded histological analysis of the
tissues was conducted by a trained pathologist at the UNMC core facility.
3.2.19 Statistical analysis
Data are presented as the means ± SD. The statistical significance was
determined using ANOVA followed by Bonferroni post hoc correction with p < 0.05 as
the minimal level of significance.
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3.3 Results and Discussion
3.3.1 The expression of CXCR4 in human CCA cells
We analyzed the expression of CXCR4 in human CCA cells Mz-ChA-1 in
normoxic (20% oxygen) and hypoxic (2% oxygen) conditions. The expression of CXCR4
mRNA was quantified with qRT-PCR. Hypoxia increased the CXCR4 expression 5.8-fold
when compared with normoxic cells (Figure 3.1A). Surface expression of the CXCR4
receptor was then analyzed by flow cytometry (Figure 3.1B). The percentage of
CXCR4-positive cells increased from 31% under normoxia to 91% in hypoxia. These
results confirmed that hypoxia induces the CXCR4 expression in CCA cells. High
CXCR4 expression typically leads to increased cell motility, migration and invasion,
which leads to enhanced metastasis [158].
3.3.2 Cytotoxicity of polymer PCX
To avoid the effect of PCX cytotoxicity on the migration activity, we carefully
selected a safe concentration of PCX. PCX at the concentration of 3 µg/mL showed no
cytotoxicity in either normoxia or hypoxia (Figure 3.2).
3.3.3 Inhibition of pErk
AMD3100 is a highly specific nM inhibitor of CXCR4. Here, 300 nM of AMD3100
was selected as an effective and safe positive control of CXCR4 inhibitor. To confirm the
CXCR4 inhibition activity of PCX in CCA cells, the downstream extracellular-signalregulated kinase (Erk) signaling pathway of CXCR4 was checked by Western blot
analysis. Erk is a main downstream signaling pathway of CXCR4/CXCL12 axis and
regulates cell survival, migration and invasion. As shown in Figure 3.3, AMD3100
specifically inhibited SDF-1-induced phosphorylation of Erk in Mz-Cha-1 cells. PCX
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retained the activity to inhibit pErk in a similar efficiency as AMD3100, which confirmed
the CXCR4 inhibiting capability of PCX.
3.3.4 Inhibition of FBS-induced cancer cell migration
The anti-migration activity of PCX was evaluated and compared with a small
molecule CXCR4 inhibitor AMD3100. As shown in Figure 3.4, hypoxia increased the
FBS-induced migration of the CCA cells ~3 fold when compared with normoxic
conditions. AMD3100 effectively inhibited the migration under both normoxia (57%
inhibition) and hypoxia (63% inhibition). Interestingly, PCX showed better anti-migration
activity and almost completely inhibited migration of the CCA cells in both conditions
(95 % inhibition in normoxia, 97% inhibition in hypoxia). To further understand why PCX
presented such a superior activity, we hypothesized that PCX affected additional
signaling pathways involved in cell motility.
3.3.5 Inhibition of LPA-induced cancer cell migration
The bioactive phospholipid lysophosphatidic acid (LPA) and its G-protein-coupled
receptors play an important role in cancer migration, invasion and metastasis through
regulating GTPases Ras, Rho, and Rac pathways. These LPA-regulated GTPases are
normally overexpressed in human CCA and involved in the invasion and metastasis
process. Inhibition of LPA signaling represents an effective approach to inhibit CCA cells
migration [159-162]. Here, we performed a migration assay using LPA as the
chemoattractive agent. As shown in Figure 3.5, LPA treatment induced the migration of
CCA cells. Hypoxia also increased the LPA-induced migration when compared with
normoxic conditions. As expected, AMD3100 failed to inhibit the migration under both
normoxia and hypoxia. However, PCX effectively inhibited LPA-induced migration with
59 % inhibition observed in normoxia and 65% inhibition found in hypoxia. AMD3100
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reduced CCA cells invasiveness through CXCR4 pathway. However, PCX inhibited
invasiveness not only through CXCR4 pathway but also LPA signaling. These findings
support the utility of PCX as a potential antimetastatic therapy due to more efficient
prevention of CCA migration through multiple pathways than conventional CXCR4
inhibitor.
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Figure 3.1. CXCR4 level analysis. (A) CXCR4 mRNA expression in Mz-ChA-1 cells
quantified by qRT-PCR. (B) CXCR4 expression on Mz-ChA-1 cell surface measured by
flow cytometry. The percent of CXCR4-positive cells and mean fluorescence intensity
(MFI) were analyzed using FlowJo software.
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Figure 3.2. Cytotoxicity of PCX in Mz-ChA-1 cells after incubation for 48 h by CellTiterBlue viability assay.
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Figure 3.3. Inhibition of pErk by PCX. Mz-Cha-1 cells were treated with AMD3100 (300
nM), PCX (3 μg/mL) for 4 h followed by 20 min incubation with SDF-1 (100 ng/mL).
Then, cells were lysed for Western blot analysis. GAPDH and Erk were used as
housekeeping controls. Quantification of Western blot bands was performed using
ImageJ software.
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Figure 3.4. Inhibition of FBS-induced cancer cell migration in normoxia and hypoxia. MzChA-1 cells were treated with AMD3100 (300 nM) or PCX (3 µg/mL) for 48 h and then
allowed to migrate through a transwell membrane insert (3 × 104 cells per insert) upon
stimulation with 10 % FBS for 12 h. Three 20× imaging areas were randomly selected for
each insert and each group was conducted in triplicate. Data are shown as mean ± SD
(n = 3). **P < 0.01, ***P < 0.001.
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Figure 3.5. Inhibition of lysophosphatidic acid (LPA)-induced cancer cell migration in
normoxia and hypoxia. Mz-ChA-1 cells were treated with AMD3100 (300 nM) or PCX (3
µg/mL) for 48 h and then allowed to migrate through a transwell membrane insert (6 ×
104 cells per insert) upon stimulation with LPA (20 µM) for 12 h. Three 20× imaging
areas were randomly selected for each insert and each group was conducted in
triplicate. Data are shown as mean ± SD (n = 3). ***P < 0.001.
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3.3.6 Preparation and characterization of nanoparticles
Besides inhibiting CXCR4, PCX are polycations that form polyplexes with nucleic
acids. The ability of PCX to form nanoparticles with miRNA was first evaluated using
agarose gel electrophoresis. Nanoparticles were prepared by adding PCX to anti-miRNA
solution at increasing polycation/anti-miRNA ratios (Figure 3.6A). PCX fully condensed
the miRNA at and above PCX/miRNA (w/w) ratios of 2. Partial condensation was
observed at lower w/w ratios (0.5-1) as indicated by the smear of the RNA in the gel.
Hydrodynamic size and ζ-potential of PCX/anti-miRNA nanoparticles (w/w = 2) were
measured by dynamic light scattering. As shown in Figure 3.6B, nanoparticles exhibited
size of 67.5 ± 0.3 nm with low polydispersity index (0.10 ± 0.05). The nanoparticles
presented positive surface charge with ζ potential of 21.5 ± 1.3 mv (Figure 3.6C). The
shape and morphology of the nanoparticles were analyzed by transmission electron
microscopy (TEM) (Figure 3.6D) and they were found as uniform particles with mostly
spherical morphology. Release of the miRNA from the particles was analyzed by heparin
displacement assay. The nanoparticles completely released miRNA above 160 μg/mL
heparin (Figure 3.6E). Poor stability against degradation by serum nucleases hinders
the in vivo application of miRNA. We studied the serum stability of PCX/anti-miRNA
nanoparticles in 50% FBS at 37 °C using gel electrophoresis (Figure 3.6F). Naked antimiRNA was rapidly degraded within 2 h of serum incubation. The PCX/anti-miR-210
nanoparticles protected the anti-miRNA for at least 8 h. Intact anti-miRNA was observed
even after serum incubation for 24 h. This result confirmed the improved serum stability
provided by the PCX particles.
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Figure 3.6. Physicochemical characterization of PCX/anti-miRNA nanoparticles. (A) antimiRNA condensation by PCX using agarose gel electrophoresis. (B) Hydrodynamic size
distribution of PCX/anti-miRNA nanoparticles (w/w=2). (C) -potential of PCX/antimiRNA nanoparticles (w/w=2). (D) TEM image of PCX/anti-miRNA nanoparticles
(w/w=2). (E) Heparin induced anti-miRNA release from the PCX/anti-miRNA
nanoparticles (w/w=2) with increasing concentrations of heparin. (F) Serum stability
assays of naked anti-miRNA and PCX/anti-miRNA nanoparticles. Agarose gel
electrophoresis of samples after treatment with serum.

73

3.3.7 In vitro delivery of anti-miRNA
After preparation and characterization of the nanoparticles, we examined their
delivery to CCA cells. We prepared PCX nanoparticles using fluorescently labeled PCX
(AF647-PCX) and anti-miRNA (FAM-anti-miRNA). Mz-ChA-1 cells were incubated in
normoxic conditions with the AF647-PCX/FAM-anti-miRNA (w/w = 2) for 4 h and
observed under confocal microscope. As shown in Figure 3.7A, both AF647-PCX (red)
and FAM-anti-miRNA (green) were observed in the Mz-ChA-1 cells after 4 h of
incubation, indicating effective uptake and internalization of the nanoparticles. Partial
colocalization of the PCX and miRNA fluorescence (yellow) suggested that at least part
of the particles remained assembled in the cells. Disassembly of the significant fraction
of the nanoparticles was evident from the separation of the PCX and miRNA
fluorescence signals. The disassembly of the nanoparticles is important for delivery of
bioavailable miRNA inhibitors.
Cell uptake was also quantified by flow cytometry (Figure 3.7B). We found that
~96% CCA cells have internalized both PCX and anti-miRNA. We also quantified the
cellular uptake of nanoparticles in hypoxia and found no difference in the uptake
percentage or mean fluorescence intensity when compared with the above results in
normoxia (Figure 3.8A). The lack of difference despite large increase in CXCR4
expression in hypoxic cells suggests that CXCR4 was not directly involved in the cell
uptake of the particles. This conclusion was further supported by a competition assay in
which pretreatment of cells with AMD3100 failed to inhibit the internalization of the
nanoparticles (Figure 3.8B).
Endosomal escape is an important step in delivery of cytoplasmically active
nucleic acids like miRNA. Intracellular distribution and trafficking of the PCX
nanoparticles were studied using confocal microscopy. Mz-ChA-1 cells were incubated
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with PCX/FAM-anti-miRNA nanoparticles for 4 h and lysosomes were stained with
LysoTracker Red (Figure 3.7C). The fluorescence of the FAM-miRNA (green) was
localized predominantly in the cytoplasm with only a limited extent of co-localization with
the LysoTracker signal (red). This result confirmed endosomal escape of the
nanoparticles.
After reaching cytoplasm, free anti-miRNA can inhibit targeted mature miRNA
and result in therapeutic effect. Transfection activity was evaluated using nanoparticles
prepared with anti-miR-210 and its negative control (anti-miR-NC). CCA cells were
treated with PCX/ miRNA under normoxia or hypoxia and miR-210 expression was
measured using qRT-PCR (Figure 3.7D). As expected, hypoxia induced a 6-fold
upregulation of miR-210 expression. Incubation with PCX/anti-miR-210 significantly
downregulated the miR-210 levels under both normoxia (~57% decrease) and hypoxia
(~85% decrease). PCX/anti-miR-NC had no effect on miR-210 expression. These results
confirmed effective delivery of functional anti-miR-210 into CCA cells and inhibition of
the targeted miRNA by the PCX nanoparticle.
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Figure 3.7. Effective delivery of anti-miRNA to CCA cells. (A) Confocal microscopic
images of Mz-ChA-1 cells incubated with AF647-PCX/FAM-anti-miRNA for 4 h. (B) Flow
cytometry analysis of cells treated with AF647-PCX/FAM-anti-miRNA for 4 h. (C)
Intracellular trafficking of AF647-PCX/anti-miRNA in cells after 4 h of incubation. (D)
MiR-210 expression in normoxic and hypoxic conditions measured by TaqMan qRTPCR in Mz-ChA-1 cells after treatment with PCX/anti-miRNA for 48 h. Data are shown
as mean ± SD (n = 3). **P < 0.01, ***P < 0.001.
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Figure 3.8. Flow cytometry analysis of cellular uptake. (A) Flow cytometry analysis of
cells treated with nanoparticles (NP) AF647-PCX/FAM-anti-miRNA for 4 h under
hypoxia. Pretreatment of Mz-ChA-1 cells with AMD3100 (100 µM) for 0.5 h for cellular
uptake competition assay. (B) Quantification of cellular uptake is shown by mean
fluorescence intensity (MFI) under normoxia and hypoxia.
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3.3.8 Anticancer activity in vitro

The CCA cell killing activity of PCX/anti-miR-210 was first studied by determining
apoptosis in the treated cells using Annexin V assay (Figure 3.9A). PCX/anti-miR-210
treatment increased the number of apoptotic cells (~32 %) and necrotic cells (∼13 %)
compared with the control groups. This pro-apoptotic effect of the nanoparticles was
further corroborated by staining with DAPI and evaluation based on nuclear morphology.
Upon treatment with PCX/anti-miR-210, Mz-ChA-1 cells demonstrated at least a 26%
increase in apoptosis compared to cells treated with PCX/anti-miR-NC (Figure 3.9B).
The PCX/anti-miR-210 nanoparticles also increased caspase 3/7 activity (∼3.2 fold) in
the CCA cells (Figure 3.9C), validating that the nanoparticles induced caspase
activation, apoptotic nuclear morphology, and externalization of phosphatidylserine.
Next, we studied the contribution of PCX/anti-miR-210 nanoparticles to the overall cell
killing activity in Mz-ChA-1 cells using cell viability assay (Figure 3.9D). PCX/anti-miR210 exhibited significantly higher cell killing activity (∼28 %) than the untreated and miRNC controls. Colony formation assay was also performed to study the effect of the
nanoparticles on tumorigenic potential of the CCA cells (Figure 3.9E). Treatment with
PCX/anti-miR-210 reduced colony formation by 92 % compared to PBS. As expected,
CXCR4 inhibition by PCX alone had no direct cell killing effect in the CCA cells. Overall,
the combined results from the anticancer activity assays confirmed promising activity of
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the PCX/anti-miR-210 nanoparticles in CCA cells due to their effect on apoptosis and
colony formation.

Cancer stem cells play important roles in growth, recurrence, and metastasis.
CXCR4/CXCL12 axis is involved in modulating the cancer stem cell niche. Inhibition of
CXCR4/CXCL12 can decrease cancer stem cells through reducing phosphorylation of
ERK and STAT3 [163, 164]. Knockdown of miR-210 previously reduced stemness of
cancer cells by rescuing the expression of Myc antagonist protein [165]. The combined
inhibition of CXCR4 and miR-210 was thus expected to cooperatively reduce stemness
of the CCA cells. Aldehyde dehydrogenase (ALDH) is a reliable marker for cancer stem
cells which exhibit high ALDH enzymatic activity. The Mz-ChA-1 cells were treated with
the particles, incubated with Aldefluor fluorescent reagent, and ALDH activity analyzed
by flow cytometry (Figure 3.9F). In the untreated cells, the ALDH positive subpopulation
of CCA cells was 4.6 %. Treatment with PCX/anti-miR-NC reduced the ALDH+
population to 1.4 %. Further decrease to 0.8% was observed in cells treated with the
combined PCX/anti-miR-210 nanoparticles. Tumor spheroid formation assay was then
used to validate the effect of the nanoparticles on cancer stem cells. Compared with the
untreated (PBS) control group with large and abundant tumor spheroids, PCX/anti-miRNC reduced the formation of large spheres. PCX/anti-miR-210 treatment further reduced
the activity of cancer cells to form tumor spheroids as indicated by the formation of small
and fragmentary spheroids (Figure 3.9G). Based on the combined evidence from the
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ALDH and tumor spheroid assays, we confirmed that both CXCR4 antagonism by PCX
and miR-210 inhibition by anti-miR-210 contributed to the reduction of stemness in CCA
cancer cell.

3.3.9 Chemosensitizing effect of the nanoparticles

Chemotherapy using GEM and CDDP has limited therapeutic effect in CCA
patients due to drug resistance. Cancer stem cells have been shown to be involved in
drug resistance through multiple cellular and molecular mechanisms. Decrease of the
cancer stem cell population thus emerged as a promising approach to overcome therapy
resistance and improve efficacy of cancer therapy [166]. After confirming the ability of
the nanoparticles to decrease stemness of the CCA cells, we aimed to study whether
PCX/anti-miRNA nanoparticles could reverse drug resistance and sensitize CCA cancer
cells to chemotherapy. Mz-ChA-1 cells were treated with GEM/CDDP or
GEM/CDDP+PCX/anti-miRNA under both normoxia and hypoxia. Then, cell viability was
measured and half-maximal inhibition concentrations (IC50) of the GEM/CDDP
combination were calculated. Treatment with PCX/anti-miR-NC (anti-miRNA 100 nM) in
normoxia had no direct cell killing effect but the CXCR4 inhibition by the particles
sensitized the cells to the effects of GEM/CDDP as indicated by the decrease of IC50
from 1.48 µg/mL to 0.49 µg/mL (Figure 3.10A). Combining the CXCR4 inhibition with
miR-210 inhibition further enhanced the chemosensitizing effect of the particles (IC50
~0.14 µg/mL). Incubation of the CCA cells in hypoxic conditions greatly increased
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resistance to GEM/CDDP treatment as shown by the more than 3-fold increase of IC50
to >5 µg/mL. Both PCX/anti-miR-NC and PCX/anti-miR-210 nanoparticles sensitized the
cancer cells to GEM/CDDP therapy in hypoxic conditions.

The chemosensitizing effect of the PCX/anti-miR-210 nanoparticles was further
investigated using synergy analysis. Cell viability was measured in CCA cells treated
with different doses and ratios of PCX/anti-miR-210 and GEM/CDDP. Combenefit
software was then used to calculate synergy scores for each combination. A positive
score (0-100) indicates synergy, a score of 0 is additive, and a negative score indicates
antagonism. Higher score indicates stronger synergistic effect. The mapped surface of
synergy/antagonism with the Bliss model is shown in Figure 3.10B. In normoxia,
PCX/anti-miR-210 and GEM/CDDP showed synergistic cell killing effect with a score of
~30. Much stronger synergy of PCX/anti-miR-210 and GEM/CDDP was achieved under
hypoxia with a score of ~60. These results confirmed that PCX/anti-miR-210 sensitized
the CCA cells to chemotherapy in a synergistic manner and reversed hypoxia-induced
drug resistance.

81

Figure 3.9. Therapeutic effect of nanoparticles in vitro. (A) Mz-ChA-1 cells were treated
with PCX/anti-miRNA nanoparticles (100 nM anti-miRNA) for 48 h. Flow cytometry
analysis of apoptosis was performed using the Annexin V-FITC/PI staining. (B) Apoptotic
nuclei were counted after DAPI staining and expressed as a percent of total nuclei. (C)
Quantitation of caspase 3/7 activity in cells. (D) Cell viability measured by CellTiterBlue
assay after treatment for 48 h. Results are normalized to the viability of PBS treated
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cells. (E) Quantification and representative images of colonies from the colony formation
assay for 14 days. (F) ALDH activity in the CCA cells by flow cytometry after treatment
with nanoparticles. Upper panels: Representative plot showing the percentage of ALDHpositive population. Lower panels: negative control after addition of ALDH inhibitor
DEAB. (G) Tumor spheroid formation in CCA cells treated with the nanoparticles and
then cultured for 14 days. Data are shown as mean ± SD (n = 3). **P < 0.01, ***P <
0.001.
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Figure 3.10. Nanoparticles sensitize CCA cells to chemotherapy. (A) Cell viability assay
of Mz-ChA-1 cells after treatment with gemcitabine/cisplatin (GEM/CDDP, w/w=10),
GEM/CDDP + PCX/anti-miR-NC, and GEM/CDDP + PCX/anti-miR-210 (anti-miRNA100
nM) for 48 h under both normoxia and hypoxia. IC50 values in combined GEM/CDDP
concentrations calculated from the dose–response curves. Data are shown as mean ±
SD (n = 3). (B) Synergy calculations of the combination effects between PCX/anti-miR210 and GEM/CDDP treatments. Cells were treated with indicated concentrations of
GEM/CDDP (w/w=10) and PCX/anti-miR-210 plus GEM/CDDP for 48 h. The data were
analyzed using Combenefit software (Cancer Research UK Cambridge Institute).
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3.3.10 Biodistribution
Following the promising in vitro findings, we explored the delivery efficacy of the
nanoparticles to tumors in vivo. Fluorescently labeled nanoparticles (AF647-PCX/FAManti-miRNA) were administered intravenously into mice bearing xenograft Mz-ChA-1
tumors. Following animal sacrifice 24 h post injection, we measured ex vivo fluorescence
(AF647) in the excised tissues to analyze the biodistribution (Figure 3.11A and B). We
observed significant tumor accumulation of the nanoparticles. As expected, the
nanoparticles were also found in the liver, spleen and lung. To evaluate the ability of the
nanoparticles to deliver both PCX and anti-miRNA into the tumors, frozen tumor sections
were observed under confocal microscope (Figure 3.11C). Both AF647-PCX (red) and
FAM-anti-miRNA (green) fluorescence were clearly present in the tumor. The high
colocalization (yellow) of AF647-PCX and FAM-anti-miRNA also indicated good stability
of the nanoparticles during systemic delivery.
3.3.11 In vivo therapeutic effect
Therapeutic efficacy of the nanoparticles was tested in xenograft CCA model in
nude mice. We have confirmed presence of hypoxic tumor microenvironment needed for
the mechanism of action of our PCX/anti-miR-210 nanoparticles using pimonidazole
staining in frozen tumor sections (Figure 3.12). Systemic intravenous treatment with the
PCX/anti-miR-210 nanoparticles effectively inhibited tumor growth (51%) when
compared with untreated (PBS) mice (Figure 3.13A). Treatment with control PCX/antimiR-NC nanoparticles or with the GEM/CDDP chemotherapy showed negligible effect
on the tumor growth. The results showed that only CXCR4 blockade by PCX/anti-miRNC nanoparticles did not inhibit CCA tumor growth significantly. Downregulation of miR210 and inhibition of CXCR4 by PCX/anti-miR-210 nanoparticles cooperatively achieved
antitumor activity. GEM/CDDP presented chemotherapeutic resistance and failed to
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inhibit tumor growth. We have used suboptimal dose of GEM/CDDP (GEM 15 mg/kg,
CDDP 1.5 mg/kg) to better demonstrate the benefits of the nanoparticles. When we
treated the animals with the combination of PCX/anti-miR-210 and GEM/CDDP, we
observed greatly enhanced tumor growth inhibition (~79%), indicating PCX/anti-miR-210
nanoparticles sensitized the tumors to chemotherapy. At the end of the study, tumors
were photographed (Figure 3.13B and C) and the weights of the tumors recorded
(Figure 3.13D). The mean tumor weight in the PCX/anti-miR-210 group (~0.34 g) was
significantly lower than the weight in the PCX/anti-miR-NC group (~0.68 g) and the
untreated group (~0.81 g). Combination PCX/anti-miR-210 with GEM/CDDP resulted in
the lowest tumor weight (~0.15 g). These findings confirmed strong antitumor and
chemosensitizing effect of the PCX/anti-miR-210 nanoparticles in CCA.
Immunohistochemical staining of cleaved caspase-3 (CC3) in the tumors was used to
validate the proapoptotic activity of the nanoparticles (Figure 3.13F). When compared
with the PBS group (2% CC3 positive cells), the PCX/anti-miR-210 treatment increased
the fraction of apoptotic CC3 positive cells to ~10%. Combination of PCX/anti-miR-210
and GEM/CDDP showed even higher proapoptotic activity, with 19% of CC3 positive
cells. Analysis of the H&E tumor sections also suggested considerably enhanced
necrosis in the PCX/anti-miR-210 and GEM/CDDP combination group when compared
with the control groups. As shown by the unchanged body weight during the treatment,
PCX/anti-miR-210 had no apparent signs of gross toxicity (Figure 3.13E). The H&E
staining of major organs demonstrated no obvious tissue damage when compared to the
PBS group (Figure 3.14). Due to the low dose of the chemotherapy drugs in this study,
we have observed no reduction in body weight or presence of tissue injury caused by
the GEM/CDDP either.
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Figure 3.11. Biodistribution of the nanoparticles in xenograft MZ-ChA-1 tumor after
intravenous injection. (A) Ex vivo images of the tumors and other tissues 24 h
postinjection of AF647-PCX/FAM-anti-miRNA nanoparticles (Ex = 640 nm, Em = 680
nm). (B) Semiquantitative analysis of the nanoparticle biodistribution 24 h postinjection.
Results are expressed as mean fluorescence intensity ± SD (n = 3). (C) Confocal
images of frozen tumor sections. PCX is shown in red (AF647), anti-miRNA in green
(FAM) and the nucleus in blue (DAPI).
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Figure 3.12. Hypoxia visualization in xenograft Mz-ChA-1 tumors. Representative
confocal images of frozen tumor sections stained with the pimonidazole antibody
(green).
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Figure 3.13. Antitumor efficacy in CCA xenograft model. (A) Mz-ChA-1 tumor growth
after intravenous injection of PCX/anti-miRNA (2.4 mg/kg PCX, 1.2 mg/kg anti-miRNA)
and intraperitoneal injection of GEM/CDDP (15 mg/kg GEM, 1.5 mg/kg CDDP). Data are
shown as mean ± SD (n = 5). (B) Representative images of the mice on day 22. (C)
Tumor tissues resected from mice on day 22. (D) Weights of tumors collected from the
sacrificed mice. Data are shown as mean ± SD (n = 5). (E) Body weight during the
treatment. Data are shown as mean ± SD (n = 5). (F) Cleaved caspase-3
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immunohistochemistry analysis (magnification 40×) and H&E staining (magnification
20×) of tumor tissues after various treatments. The percentage (%) of cleaved caspase-3
positive cells in tumors. Data are shown as mean ± SD (n = 3). *P < 0.05, **P < 0.01,
***P < 0.001
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Figure 3.14. Histological observation of tissue sections from major organs of mice after
treatment. The organ sections were stained with hematoxylin and eosin (H&E). The
images were taken under a light microscope (×40).
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3.4 Conclusion
In this study, we have developed an innovative combination nanoparticle
treatment approach through simultaneous inhibition of CXCR4 and miR-210. The results
showed that CXCR4-inhibiting polycation PCX could efficiently block the hypoxiainduced migration of CCA cells apparently through CXCR4 and LPA pathways.
PCX/anti-miRNA nanoparticles delivered functional anti-miRNA to the CCA cells and
downregulated miR-210 expression, which resulted in significant cell killing through
induction of apoptosis. PCX/anti-miR-210 nanoparticles sensitized CCA cells to
GEM/CDDP chemotherapy by reducing stemness and synergistically reversed hypoxiainduced drug resistance. The combination nanoparticles achieved effective systemic
delivery to CCA xenograft tumors and enhanced antitumor therapy in vivo through direct
tumor growth inhibition and chemotherapy sensitization. The nanoparticles represent
promising dual-function delivery platform for miRNA delivery and provide safe and
effective nanomedicines for systemic CCA therapy. Future studies will focus on the
evaluation of the nanoparticles in orthotopic and metastatic CCA animal models to
facilitate their clinical translation.
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Chapter 4 – Delivery of siRNA and miRNA with CXCR4 targeted nanoparticles for
metastatic pancreatic cancer therapy
4.1. Introduction
Pancreatic cancer (PC) is among the most lethal human cancers with a 5-year
survival of less than 5% and predicted to be the second leading cause of cancer-related
death by 2030 in United States [167, 168]. The high mortality of PC is mainly due to late
diagnosis, widespread metastasis, poor delivery of therapeutics and resistance to
available therapies [169, 170]. FOLFIRINOX has resulted in the best therapeutic efficacy
in PC patient to date, but the median survival still remains only 11.1 months [171]. These
therapeutic challenges highlight the urgent need to develop new therapeutics for PC
therapy.
The C-X-C receptor type 4 (CXCR4) and its ligand (CXCL12) play a key role in in
tumor growth, metastasis, angiogenesis and tumor microenvironment, which make them
potential targets for PC therapy [11, 12]. The binding of CXCL12 to CXCR4 activates
multiple pathways including SHH, Wnt and MMP to promote migration and invasion of
cancer cells. CXCR4 then facilitates metastasis of the primary tumor cells to CXCL12
expressing sites including liver, lymph nodes, lung, and bone marrow [141, 172].
Inhibition of CXCR4/CXCL12 axis with CXCR4 antagonists decreased the invasion and
metastasis of PC cells [38, 173, 174]. Current evidence strongly supports the potential of
CXCR4 inhibition to inhibit metastasis in PC.
Small interfering RNA (siRNA) and microRNA (miRNA) are promising
therapeutics for PC through RNA interference-mediated oncogene silencing. SiRNAs are
synthetic RNA duplexes (19–25 bp in length) designed to specifically target a particular
mRNA for degradation. MicroRNAs (miRNAs) are small noncoding RNAs (~22
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nucleotide) that post-transcriptionally regulate gene expression via imperfect pairing. A
miRNA typically targets multiple genes simultaneously and regulated multiple signaling
pathways involved in various cancers including PC [175-179]. The combination
delivering of siRNA and miRNA represents an attractive strategy to improve anticancer
efficacy via simultaneously silencing a specific oncogene strongly and regulating a broad
range of cancer related genes [180, 181].
Oncogene mutations of the GTPase KRAS are highly prevalent in PC and
emerged as key drivers of PC initiation, progression and metastasis [182-184]. Inhibition
of oncogenic KRAS with genetic manipulation inhibits PC progression in mice [185].
However, KRAS remains a largely undruggable therapeutic target; Pharmaceutical
companies and academic laboratories failed to develop small molecule inhibitors of
KRAS after decades of trying. SiRNA targeting KRASG12D, which is the most common
KRAS mutation, improved overall survival of mice models and represented an effective
KRAS targeted therapeutic for PC therapy [186]. Moreover, miR-210 is another attractive
target for cancer therapy. Hypoxia in PC induces the overexpression of miR-210, which
facilitates the adaptation of cancer cells to the hypoxic microenvironment via multiple
signaling pathways [91, 187-189]. MiR-210 participates in the regulation of cancer
proliferation, apoptosis, metastasis, DNA repair, cell metabolism, and drug resistance
[94, 154, 190, 191]. Inhibition of miR-210 provides an effective option for the treatment of
PC.
Despite the potential of siRNA and miRNA in PC therapy, their clinical translation
is mainly limited by lack of delivery system. SiRNA/miRNA have similar physicochemical
properties (double-stranded RNAs with ~22 nucleotides) and the same intracellular site
of action (cytoplasm). Similar delivery systems enable to deliver both siRNA and miRNA.
Polycations stand among the most investigated delivery platforms, which form
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polyplexes with siRNA/miRNA and promote their delivery by protecting them from
degradation and overcoming multiple biological barriers [156, 192]. Traditional
polycations are pharmacologically inert with no inherent anticancer activity.
Pharmacologically active polycations present as a new class of combination cancer
therapies with advantages including simple formulation and high content of active agents
[6]. Polymeric CXCR4 antagonists (PCX), which are mainly composed of FDA-approved
CXCR4 inhibitor AMD3100, are able to block CXCR4/CXCL12 axis and deliver siRNA or
miRNA for combined cancer therapy [21, 59, 157]. Considering the key roles of CXCR4,
KRAS and miR-210 in PC, we hypothesized that combining inhibition of CXCR4, silence
of KRAS and inhibition of hypoxia-inducible miR-210 would cooperatively enhance the
therapy of PC. To test this hypothesis, we used PCX to form nanoparticles with both
siKRAS and miR-210 inhibitor and evaluated their delivery activity and anticancer
efficacy in PC both in vitro and in vivo.
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4.2. Materials and methods
4.2.1 Materials
Cholesterol-modified polymeric CXCR4 inhibitors PCX was synthesized and
characterized as previously described. Succinimidyl ester of Alexa Fluor® 647 carboxylic
acid was from Life Technologies (Eugene, OR). AlexaFluor 647 labeled PCX polymers
(AF647-PCX) were produced according to manufacturer’s instructions and purified by
dialysis to remove unreacted dye. AMD3100 was from Biochempartner (Shanghai,
China). Dulbecco’s modified Eagle medium (DMEM), Dulbecco’s phosphate buffered
saline (PBS), trypsin, penicillin, streptomycin and fetal bovine serum (FBS) were from
Thermo Scientific (Waltham, MA). Hsa-miR-210-3p-Hairpin Inhibitor (anti-miR-210,
mature miRNA sequence: 5′-CUGUGCGUGUGACAGCGGCUGA-3′), negative control
miR-NC inhibitor (anti-miR-NC, mature miRNA sequence: 5′UCACAACCUCCUAGAAAGAGUAGA-3′), siRNA targeting KRAS (siKRAS, sense
sequence, 5′-GUUGGAGCUGAUGGCGUAGdTdT-3′), negative control siRNA (siNC,
sense sequence, 5′- UCACAACCUCCUAGAAAGAGUAGA-3′) and carboxyfluorescein
(FAM) labeled FAM-siRNA were purchased from Dharmacon (Lafayette, CO). Cell
culture inserts (for 24-well plates, 8.0 μm pores, Translucent PET Membrane, cat#
353097) were purchased from BD Biosciences (Billerica, MA). Real-time (RT)-PCR
primers were purchased from Invitrogen (Carlsbad, CA). Allophycocyanin (APC) mouse
anti-human CXCR4 antibody and APC mouse lgG2a, ĸ isotype controls were from BD
Biosciences (San Jose, CA). All other reagents were from Fisher Scientific and used as
received unless otherwise noted.
4.2.2 Cell culture
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Primary tumor cell line KPC8060 derived from KPC pancreatic ductal
adenocarcinoma mouse model (KrasLSL-G12D/+; Trp53LSL-R172H/+; Pdx-1-Cre) were provided
by Dr. James Grunkemeyer at UNMC. KPC cells were grown in high-glucose DMEM
supplemented with 10% FBS, penicillin (100 U/mL) and streptomycin (100 μg/mL) at
37 °C with 5% CO2 in a humidified chamber.
4.2.3 Preparation and characterization of nanoparticles
PCX/(siRNA+miRNA) nanoparticles were prepared by adding predetermined
volume of PCX to a siRNA and miRNA solution (siRNA:miRNA = 1 (mol:mol), 20 μM in
10 mM HEPES pH 7.4) to achieve the desired w/w ratio and vigorously vortexed for 10
s. Nanoparticles were then incubated at room temperature for 20 min before further use.
The ability of PCX to condense siRNA and miRNA was determined by electrophoresis in
a 2% agarose gel containing 0.5 μg/mL ethidium bromide (EtBr). Nanoparticles formed
at various polycation-to-(siRNA+miRNA) weight ratios were loaded (20 μL of the sample
containing 0.5 μg of miRNA and siRNA) and run for 15 min at 100 V in 0.5 ×
Tris/Borate/EDTA buffer. The gels were visualized under UV illumination with a KODAK
Gel Logic 100 imaging system. Hydrodynamic diameter and zeta potential of the
nanoparticles were determined by dynamic light scattering (DLS) using a ZEN3600
Zetasizer Nano-ZS (Malvern Instruments Ltd., Massachusetts, USA). Morphology was
observed under transmission electron microscopy (TEM, Tecnai G2 Spirit, FEI
Company, USA) using NanoVan® negative staining (Nanoprobes, USA). The
morphology was also observed using MultiMode Atomic force microscopy (AFM)
NanoScope IV system (Bruker Instruments, Santa Barbara, CA) operating in tapping
mode.
4.2.4 Quantitative real-time polymerase chain reaction (qRT-PCR)
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Cells were seeded in 12-well plates at 5 × 104 cells per well 24 h prior to
treatment. Then, the cells were incubated with the nanoparticles containing anti-miRNA
(50 nM) and siRNA (50 nM) in 1 mL of medium for 48 h. The mirVana miRNA Isolation
Kit (Ambion, USA) was used for total RNA extraction from cultured cells. The expression
levels of miR-210 were evaluated by TaqMan qRT-PCR. 10 ng of total RNA was
converted into cDNA using specific primers for miR-210 (or the internal control Z30
(Applied Biosystems, Foster City, CA)) and the TaqMan microRNA reverse transcription
kit (Applied Biosystems). qRT-PCR was performed using TaqMan Universal Master Mix
II, No AmpErase UNG (2×) and specific primers for miR-210 or Z30 (Applied
Biosystems, Foster City, CA) on a Rotor-Gene Q instrument (QIAGEN) according to the
manufacturer’s instructions. MiRNA expression levels were expressed relative to the
internal control according to the comparative threshold cycle (Ct) method. Expression of
the KRAS was quantified using SYBR Green RT-PCR. 0.5 μg total RNA was reversetranscribed to cDNA using QuantiTect reverse transcription kit (Qiagen): the relative
amount of mRNA was determined by RT-PCR on a Rotor-Gene Q instrument (QIAGEN).
The GAPDH primer assay and QuantiFast SYBR Green PCR kit (Qiagen) were used
following themanufacturer's protocol. The following primers were used: KRAS (forward
5′-CGCAGACTTACTTCCCCGGC; reverse,
5′-CGCTCAATTCCTCAACCACG). Relative mRNA expression levels were calculated
from the Ct values of the target genes and the housekeeping gene GAPDH.
4.2.5 DAPI staining assay
Apoptosis percentage was also quantified by nuclear morphology and visualized
by treatment with the fluorescent DNA-binding dye, DAPI (4′, 6-diamidine-2′phenylindole dihydrochloride). Briefly, cells were stained with 2 μg/mL of DAPI for 30
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minutes at 37 °C. Apoptotic nuclei (condensed, fragmented) were counted and
presented as a percent of total nuclei. At least 100 cells were counted per well and
experiments were performed in triplicate.
4.2.6 Colony formation
Cells were transfected with nanoparticles containing siRNA and miRNA for 4 h.
Then, transfected cells were reseeded in 12-well plates (200 cells per plate). Cells were
allowed to grow for 7 days. Cells were fixed in 100% methanol and stained with 0.2%
Crystal Violet solution for 10 min. Finally, plates were washed with distilled water and
photographed. Number of colonies in each well were quantified.
4.2.7 KPC-derived orthotopic PC model
All animal experiments followed a protocol approved by the University of
Nebraska Medical Center Institutional Animal Care and Use Committee. Orthotopic
KPC-derived model was established by orthotopic injection of KPC cells into the tail of
the pancreas. Briefly, KPC cells were trypsinized, washed and resuspended in 1:1
mixture of PBS/Matrigel. Female C57Bl/6 mice (6 weeks old) from Charles River
Laboratories were anesthetized by IP injection of ketamine/xylazine solution. The
surgical site was sterilized and a 1-cm incision was made in the peritoneum at the midabdomen region below the sternum by scissors. 2.5 × 104 of KPC cells (40 µL) were
injected into the head of pancreas. The abdomen was closed with a 2-layer suture with
5-0 chromic catgut and soft staple. The skin staples were removed 10 days after
surgery.
4.2.8 Blood circulation time
KPC mice were IV or IP injected with AF647-PCX/FAM-siRNA nanoparticles. At
0, 0.25, 1, 4, and 24 h post injection, about 100 µL blood from the venous plexus of mice
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was collected in heparin-treated tubes and imaged with Xenogen IVIS 200 (Ex = 640
nm, Em = 680 nm). The fluorescence from each tube was analyzed by the instrument
software.
4.2.9 Biodistribution
KPC mice were IV or IP injected with AF647-PCX/FAM-siRNA nanoparticles. At
4 and 24 h post injection, the mice were sacrificed and imaged using Xenogen IVIS 200
(Ex = 640 nm, Em = 680 nm). The tumors and major organs were also harvested and
subjected to ex vivo fluorescence imaging (Ex = 640 nm, Em = 680 nm). The
fluorescence from each organ was analyzed by the instrument software. Then, the
isolated tumors were embedded in an OCT compound, cut into 10 μm sections, stained
with CD31 antibody (Cy3) and DAPI, and imaged with a confocal microscope.
4.2.10 Anticancer activity
At day 14 post-tumor inoculation, mice were randomly assigned to 5 groups (n =
5) and IP injected with PBS, PCX/(siNC+miR-NC), PCX/(siNC+miR-210),
PCX/(siKRAS+miR-NC), and PCX/(siKRAS+miR-210), respectively.
PCX/(siRNA+miRNA) nanoparticles (w/w=2, 5 mg/kg PCX, 1.25 mg/kg siRNA, 1.25
mg/kg miRNA) were injected at days 14, 16, 18, 20, 22, 24 and 26. Body weight of the
mice was recorded. On days 28, blood was drawn from the venous plexus of the eyes of
mice for whole blood analysis and serum biochemistry test. Mice were sacrificed, and all
tumor tissues and major organs were harvested, fixed in 4% paraformaldehyde,
sectioned, and stained with H&E. Blood were collected Blinded histological analysis of
the tissues was conducted by a trained pathologist at the UNMC core facility.
4.2.11 Statistical analysis
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Data are presented as the means ± SD. The statistical significance was
determined using ANOVA followed by Bonferroni post hoc correction with p < 0.05 as
the minimal level of significance.
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4.3. Results and discussion
4.3.1 Preparation and characterization of nanoparticles
The ability of PCX to condense siRNA and miRNA was evaluated using agarose
gel electrophoresis. PCX was added to siRNA and miRNA solution at increasing
polymer/(siRNA+miRNA) weight ratios (Figure 4.1A). SiRNA and miRNA was fully
condensed at and above PCX/(siRNA+miRNA) (w/w) ratios of 2. Partial condensation
was observed at lower w/w ratios (0.5-1). Hydrodynamic size and ζ-potential of
PCX/(siRNA+miRNA) nanoparticles (w/w = 2) were measured by dynamic light
scattering (Figure 4.1B and C). Nanoparticles presented sizes of 57.3 ± 0.4 nm with low
polydispersity index (0.12 ± 0.02). The nanoparticles exhibited a positive surface charge
with ζ potential of 19.5 ± 1.6 mV. The shape and morphology of nanoparticles was
further analyzed by transmission electron microscopy (TEM) and atomic force
microscopy (AFM). The nanoparticles were uniform particles with a mostly spherical
morphology (Figure 4.1D and E).
4.3.2 In vitro delivery of siRNA and miRNA
Transfection activity was evaluated using nanoparticles loaded with siKRAS and
anti-miR-210. KPC cells were treated with PCX/(siRNA+anti-miRNA) nanoparticles.
Then, KRAS mRNA and miR-210 expression was measured using qRT-PCR.
PCX/(siKNC+anti-miNC) failed to decrease KRAS mRNA and miR-210 levels. Incubation
with PCX/(siKRAS+anti-miNC) downregulated KRAS mRNA level (Figure 4.2A).
Treatment with PCX/(siNC+anti-miR-210) decreased miR-210 level in KPC cells (Figure
4.2B). PCX/(siKRAS+anti-miR-210) nanoparticles significantly downregulated both
KRAS mRNA (~54% decrease) and miR-210 levels (~53% decrease). These results
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confirmed effective delivery of functional siKRAS and anti-miR-210 into KPC cells and
inhibition of the targeted gene and miRNA by the PCX nanoparticle.
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Figure 4.1. Physicochemical characterization of PCX/(siRNA+anti-miRNA)
nanoparticles. (A) Condensation of siRNA and anti-miRNA by PCX using agarose gel
electrophoresis. (B) Hydrodynamic size distribution of PCX/(siRNA+anti-miRNA)
nanoparticles (w/w=2). (C) ζ-potential of PCX/(siRNA+anti-miRNA) nanoparticles
(w/w=2). (D) TEM image of PCX/(siRNA+anti-miRNA) nanoparticles (w/w=2). (E) AFM
image of PCX/(siRNA+anti-miRNA) nanoparticles (w/w=2).
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Figure 4.2. In vitro delivery of siRNA and miRNA. (A) KRAS mRNA and (B) miR-210
expression in KPC cells after treatment with PCX/(siRNA+anti-miRNA) for 48 h. Data are
shown as mean ± SD (n = 3). **P < 0.01, ***P < 0.001.
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4.3.3 Anticancer activity in vitro
The pro-apoptotic activity of PCX/(siRNA+anti-miRNA) was first studied by
staining with DAPI and evaluation based on nuclear morphology. Upon treatment with
PCX/(siKRAS+anti-miR-210), KPC cells demonstrated at least a 40% increase in
apoptosis compared to cells treated with PCX/(siNC+anti-miR-NC) (Figure 4.3A).
PCX/(siNC+anti-miR-210) and PCX/(siKRAS+anti-miR-NC) treatment induced only 10%
and 15% apoptosis, respectively. These results confirmed the combinational proapoptotic activity through co-delivery of siKRAS and anti-miR-210 by PCX nanoparticles.
Colony formation assay was also performed to study the effect of the nanoparticles on
the tumorigenic potential of KPC cells. In comparison with PCX/(siNC+anti-miR-NC)
group, treatment with PCX/(siKRAS+anti-miR-210) presented co-operative activity to
reduce colony formation by delivery of both siKRAS and anti-miR-210 (Figure 4.3B).
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Figure 4.3. Anticancer activity in vitro. (A) Apoptotic nuclei were counted after DAPI
staining and expressed as a percent of total nuclei. (B) Quantification and representative
images of colonies from the colony formation assay for 7 days. Data are shown as mean
± SD (n = 3). *P < 0.05, ***P < 0.001.
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4.3.4 Blood circulation time and biodistribution
To investigate the circulation time of nanoparticles in blood, AF647-PCX/FAMsiRNA nanoparticles were IV or IP injected into KPC mice. The AF647-PCX fluorescent
intensity in each group was normalized by setting 0 h intensity after IV injection as
100%. In the IV injection group, the fluorescence signal of AF647-PCX decreased
quickly, remained only 16% at 1 h and then decrease to almost 0% at 24 h due to the
fast clearance of nanoparticles from the blood (Figure 4.4A). In the IP injection group,
the fluorescence intensity firstly increased, reached 18% at 1 h, and then decreased to
0%. The fluorescence intensity after IP injection is a likely a function of absorption from
the peritoneal cavity into blood and clearance from blood.
To explore the biodistribution of nanoparticles, AF647-PCX/FAM-siRNA
nanoparticles were IV or IP injected into KPC mice. Following animal sacrifice 4h and 24
h post injection, we measured fluorescence (AF647) in the tissues after removal to
analyze the biodistribution. In the IV injection mice, the nanoparticles mainly
accumulated in the liver and presented poor tumor distribution (Figure 4.4B). The
nanoparticles were also found in the spleen and lung. In the IP injection mice, specific
accumulation of nanoparticles was observed in tumor. The tumor fluorescence intensity
increased from 4 h to 24 h due to more penetrated nanoparticles over time. At 24 h,
tumoral fluorescence intensity of IP injected mice is 16 folds higher than that of IV
injected mice. To further evaluate the ability of the nanoparticles to deliver both PCX and
siRNA into the tumors, frozen tumor sections were observed under a confocal
microscope. Both AF647-PCX (red) and FAM-siRNA (green) fluorescence were clearly
present in the tumor of IP injected mice. Importantly, the nanoparticles were delivered to
both peripheral regions and central regions of tumors indicated by widespread
fluorescence in the all tumor tissues. However, very weak AF647-PCX and FAM-siRNA
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fluorescence were found in the IV injected mice tumor (Figure 4.4C). These results
confirmed the superior capability of nanoparticles to deliver both PCX and siRNA to
orthotopic PC tumor via IP injection than via IV injection.
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Figure 4.4. The circulation time and biodistribution of nanoparticles in vivo. (A) The
circulation time of AF647-PCX/FAM-siRNA in blood after IV or IP injection. AF647-PCX
was used for visualization. Blood was drawn from mice after IV or IP injection with
AF647-PCX/FAM-siRNA nanoparticles at different time and imaged under a
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fluorescence imaging system (Ex = 640 nm, Em = 680 nm). The fluorescence intensity
of 0 h in each group was normalized as 100%. (B) The biodistribution of AF647PCX/FAM-siRNA nanoparticles in vivo. Mice were administrated with AF647-PCX/FAMsiRNA via IV or IP injection. At 6h and 24h after injection, mice were sacrificed and
imaged under a fluorescence imaging system (Ex = 640 nm, Em = 680 nm). The
harvested organs and tumors were also imaged. Semiquantitative analysis of the
nanoparticle biodistribution was performed. Results are expressed as mean
fluorescence intensity ± SD (n = 3). (C) Confocal images of frozen tumor sections. PCX
is shown in red (AF647), siRNA in green (FAM), blood vessel in white (Cy3) and the
nucleus in blue (DAPI).

111

4.3.5 Anticancer activity in vivo
Therapeutic efficacy of the nanoparticles was tested in a genetic model of
spontaneous pancreatic cancer. Mice with mutant KRAS and p53 loss (KPC) were used.
At day 14 post-tumor inoculation, mice were received multiple IP injections of
nanoparticles (Figure 4.5A). As presented by the unchanged body weight during the
treatment, PCX/(siRNA+anti-miRNA) nanoparticles had no apparent signs of gross
toxicity (Figure 4.5B). After treatment, a part of mice (5 per group) were sacrificed for
checking primary tumor size and metastasis. Treatment with control PCX/(siNC+antimiR-NC) nanoparticles showed negligible effect on primary tumor growth (Figure 4.5 C
and D). In comparison with PBS group, both PCX/(siNC+anti-miR-210) and
PCX/(siKRAS+anti-miR-NC) significantly inhibited tumor growth by 43% and 47%.
PCX/(siKRAS+anti-miR-210) treatment presented enhanced tumor growth inhibition
(~60%). These results suggested that CXCR4 inhibition alone has no effect on the
growth of primary tumor. Delivery of siKRAS or anti-miR-210 effectively inhibited tumor
growth. Co-delivery of siKRAS and anti-miR-210 in PCX nanoparticles achieved
combined siRNA/miRNA therapy against primary tumor.
Besides the inhibition activity on primary tumor, the effect of nanoparticles on
metastasis was also studied. Widespread tumor metastasis was found in range of
organs and tissues, including liver, spleen, kidney, intestine, stomach, abdominal wall
and diaphragm (Figure 4.6A and B). PCX/(siNC+anti-miR-NC) nanoparticles presented
apparent activity to inhibit metastasis, which was indicated by the reduced metastatic
frequencies in broad tissues in comparison with PBS group. This metastasis inhibition
activity was most likely due to CXCR4 inhibition endowed by PCX. The delivery of
siKRAS and anti-miR-210 inhibitor further improved the activity of nanoparticles to inhibit
metastasis. PCX/(siKRAS+anti-miR-210) completely inhibited the metastasis to all
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observed tissues except spleen (Figure 4.6B). PCX/(siKRAS+anti-miR-210) also
reduced the macro-metastasis on the surface of liver (Figure 4.6C). Moreover, HE
staining further showed the decreased tumor metastasis area in tissues (Figure 4.6D).
These results confirmed the combinational antimetastatic activity of PCX/(siKRAS+miR210) nanoparticles through simultaneous inhibition of CXCR4 and delivery of
siKRAS/miR-210 inhibitor.
PCX/(siKRAS+miR-210) was able to inhibit primary tumor growth and
widespread metastasis. Next, we aimed to study the effect of nanoparticles treatment on
survival of KPC-derived mice. In comparison with PBS group, PCX/(siNC+miR-NC)
treatment significantly increase median survival by 19%. PCX/(siNC+miR-210) and
PCX/(siKRAS+miR-NC) further prolonged the survival of mice by 31% and 34%,
respectively. PCX/(siKRAS+miR-210) nanoparticles achieved the cooperative activity to
significantly improve the survival by 50% (Figure 4.7).
3.6 Toxicity evaluation in vivo
Blood was collected from nanoparticles treated mice for whole blood analysis
and biochemistry test. As shown in Figure 4.8, PCX/(siKRAS+miR-210) nanoparticle
treatment did not alter white blood cell (WBC), lymphocyte, monocyte, neutrophil and red
blood cell (RBC) count in comparison with the PBS group, which suggested no
syndrome, such as hemolytic anemia, and acute infection was caused by the
nanoparticles. Liver enzymes and renal indicators were also measured. The
concentrations of AST, ALT, BUN and creatinine were within the normal range, which
indicated no obvious toxicity in the liver or kidney.
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Figure 4.5. Inhibition of tumor growth in vivo. (A) Scheme of nanoparticles treatment.
G1, PBS; G2, PCX/(siNC+anti-miR-NC); G3, PCX/(siNC+anti-miR-210); G4,
PCX/(siKRAS+anti-miR-NC); G5, PCX/(siKRAS+anti-miR-210). (B) Body weight during
the treatment. Data are shown as mean ± SD (n = 5). (C) Tumor tissues resected from
mice on day 28. (D) Weights of tumors collected from the sacrificed mice. Data are
shown as mean ± SD (n = 5). **P < 0.01.
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Figure 4.6. Inhibition of metastasis in vivo. (A) Tissues resected from mice on day 28.
Arrow indicated tumor metastasis. (B) Heat map of tumor metastasis frequency in
tissues. (C) Number of maco-metastasis on the surface of liver. (D) H&E staining of
tissues. G1, PBS; G2, PCX/(siNC+anti-miR-NC); G3, PCX/(siNC+anti-miR-210); G4,
PCX/(siKRAS+anti-miR-NC); G5, PCX/(siKRAS+anti-miR-210).
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Figure 4.7. Kaplan–Meier survival graph of KPC mice. Log-rank Mantel–Cox test, ***P <
0.0001.
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Figure 4.8. Whole blood and biochemistry analysis. G5, PCX/(siKRAS+anti-miR-210).
Data are shown as mean ± SD (n = 3).
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4.4 Conclusion
In this study, we developed a combination nanoparticle treatment approach
through simultaneous inhibition of CXCR4 and knockdown of KRAS and miR-210 for
metastatic pancreatic cancer therapy. CXCR4-inhibiting polycation PCX could condense
siRNA and miRNA to form nanoparticles. Nanoparticles effectively delivered siRNA and
miRNA inhibitor into PC cells and downregulated KRAS and miR-210, which resulted in
significant cell killing. The nanoparticles specifically and highly accumulated in orthotopic
tumor after IP injection. The IP injected combination nanoparticles achieved improved
survival in orthotopic pancreatic cancer mice through inhibiting both primary tumor
growth and metastasis. The nanoparticles represent a promising dual-function delivery
platform for siRNA/miRNA codelivery and provide safe and effective nanomedicines for
metastatic PC therapy.
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Chapter 5 – SUMMERY AND FUTURE DIRECTIONS
5.1 Summary
The CXCR4/CXCL12 signaling axis plays a key role in tumor growth, metastasis,
angiogenesis and cancer cell-microenvironment interaction. Inhibition of CXCR4
represents an effective strategy for metastatic cancer therapy. On the other hand,
miRNAs function as tumor suppressors or oncogenes and participate in the regulation of
tumorigenesis and progression. Inhibition of overexpressed oncogenic miRNAs or
restitution of downregulated tumor-suppressor miRNAs provides a highly promising
approach to treat cancer. Polymeric CXCR4 antagonist PCX is a dual-function
polycation to inhibit CXCR4 and deliver nucleic acids. Here, we used PCX to form
nanoparticles with therapeutic miRNA and then simultaneously delivered miRNA and
inhibited CXCR4 for combined therapy in metastatic cancer.
PCX can inhibit CCA cell migration due to its CXCR4 antagonism. The ability of
PCX to form polyplexes with nucleic acids was used for simultaneous delivery of miR200c mimic into cells. The delivery of miR-200c resulted in reduced expression of the
EMT inducer ZEB1. The combination treatment consisting of PCX and miR-200c
resulted in cooperative anti-migration activity, most likely by coupling the CXCR4 axis
blockade with EMT inhibition in the cholangiocarcinoma cells. PCX/miR-200c
nanoparticles is a promising strategy for a combination therapy involving multiple
migration pathways in metastatic CCA.
Moreover, we have developed a combination CCA treatment approach through
inhibition of CXCR4 and miR-210. PCX could efficiently block the hypoxia-induced
migration of CCA cells apparently through CXCR4 and LPA pathways. PCX/anti-miRNA
nanoparticles delivered functional anti-miRNA to the CCA cells and downregulated miR-
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210 expression, which resulted in significant cell killing through induction of apoptosis.
PCX/anti-miR-210 nanoparticles sensitized CCA cells to GEM/CDDP chemotherapy.
The combination nanoparticles achieved effective systemic delivery to CCA xenograft
tumors and enhanced antitumor therapy in vivo through direct tumor growth inhibition
and chemotherapy sensitization. The nanoparticles may represent an effective dualfunction delivery platform for miRNA delivery and provide safe and effective
nanomedicines for systemic CCA therapy.
On the other hand, we developed a combination nanoparticle treatment approach
through simultaneous inhibition of CXCR4 and knockdown of mutant KRAS and miR-210
for metastatic pancreatic cancer therapy. PCX could condense siRNA and miRNA to
form nanoparticles. Nanoparticles effectively delivered siRNA and miRNA inhibitor into
PC cells and downregulated KRAS and miR-210, which resulted in significant cell killing.
The nanoparticles specifically accumulated in orthotopic tumor after IP injection. The IP
injected combination nanoparticles achieved improved survival in orthotopic PC mice
through inhibition of primary tumor growth and metastasis. The CXCR4 targeted
nanoparticles may provide a safe and effective platform for therapeutic siRNA/miRNA
codelivery in metastatic PC therapy.
5.2 Future directions
Despite the great potential, there are still many challenges for the clinical use of
the PCX/miRNA nanomedicines. Future directions will focus on improving their in vivo
delivery to tumors. For example, recent studies reported that fluorination of polyplexes is
able to improve nucleic acid delivery activity while reducing toxicity mainly by increasing
stability and membrane transport properties [193-195]. Optimized fluorination of PCX is
thus expected to improve their in vivo efficiency. Other approaches include zwitterionic
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modifications [196, 197], and tumor targeting and penetrating moiety conjugation are
also expected to enhance in vivo delivery of these nanomedicines [198, 199].
In addition to improving delivery, we also aim to combine the CXCR4 targeted
nanomedicines with other therapies like immunotherapy. For example, recent studies
confirm that CXCR4 inhibition is able to boost the PD-1/PD-L1 pathway blockade
immunotherapy by facilitating T cell infiltration [16, 17, 200]. Intervention of PD-1/PD-L1
pathway via RNA interference (RNAi) also represents an effective approach to boost
immunotherapy [201, 202]. Accordingly, use of CXCR4 targeted nanomedicine to deliver
PD-L1 siRNA is a potential strategy for improved checkpoint blockade immunotherapy.
Future studies will also focus on the evaluation of the nanoparticles in preclinical
animal models which are representative of human disease to facilitate their clinical
translation. For example, we aim to test PCX/miR-200c and PCX/miR-210 nanoparticles
in orthotopic and metastatic CCA animal models.
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